Parkyard Hotel, Shanghai

Address: No.699 Bibo Road, Zhangjiang High-Tech Park, Pudong Newly District, Shanghai, China

Tel: +86-21 61621160; Website: http://www.parkyard.com

2014年皇后镇分子生物学(上海)会议
— 药物发现与国际合作
第六届全国药物筛选新技术研讨会
中国热带病药物与诊断创新网络第三次会议

2014 Queenstown Molecular Biology Meetings in Shanghai
— Drug Discovery and International Collaboration
The 6th National Forum on New Technologies in Drug Discovery
The 3rd Meeting of Chinese Network for Drugs and Diagnostics Innovation

2014年3月13日-14日

March 13-14, 2014

中国 • 上海 • 张江 • 博雅酒店

Parkyard Hotel, Zhangjiang, Shanghai, China



2014年皇后镇分子生物学(上海)会议
— 药物发现与国际合作
第六届全国药物筛选新技术研讨会
中国热带病药物与诊断创新网络第三次会议

2014 Queenstown Molecular Biology Meetings in Shanghai
— Drug Discovery and International Collaboration
The 6th National Forum on New Technologies in Drug Discovery
The 3rd Meeting of Chinese Network for Drugs and Diagnostics Innovation

日程
Programs

2014年3月13日-14日
March 13-14, 2014
中国 • 上海 • 张江 • 博雅酒店
Parkyard Hotel, Zhangjiang, Shanghai, China

Contents

Thursday, March 13, 2014

8:30-8:50	Host: **Professor Ming-Wei Wang** The National Center for Drug Screening, Shanghai, China
	Opening remarks: **Professor Jian Ding** Shanghai Institute of Materia Medica, Chinese Academy of Sciences
8:50-9:00	Group photo at the garden
Plenary lectures Moderator: Ming-Wei Wang	
9:00-9:35	**Garth Cooper** (The University of Manchester, UK) *Is type 2 diabetes an amyloidosis and does it really matter (to patients)?*
9:35-10:10	**Raymond Stevens** (The Scripps Research Institute, USA) *The incredible diversity of G-protein coupled receptors*
10:10-10:45	**Zihe Rao** (Tianjin International Joint Academy of Biomedicine, China) *Structural insight of HFMDV and antiviral drug discovery*
10:45-11:00	Coffee Break
Parallel session 1-1: Innovation *– Dedicated to the International Women's Day on March 8* Moderators: Daniel Hoyer and Richard D. Ye	
11:00-11:20	**Ruiping Xiao** (Peking University, China) *Cross talk between GPCR and RAGE*
11:20-11:40	**Deborah Hay** (Maurice Wilkins Centre and University of Auckland, New Zealand) *Targeting class B GPCRs to treat migraine, cancer and obesity*
11:40-12:00	**Beili Wu** (Shanghai Institute of Materia Medica, Chinese Academy of Sciences) *Structural studies of HIV-1 co-receptors CXCR4 and CCR5*
12:00-12:20	**Xin Xie** (The National Center for Drug Screening, China) *Targeting G protein-coupled receptors for the treatment of autoimmune diseases*
	Lunch break and Technology Showcase 1 (12:20-13:20)
12:30-12:40	**Agilent Technologies** *A pathway-centric approach to multi-omics research powered by GeneSpring analytics*
12:40-12:50	**Molecular Devices** *Molecular Devices total solution in drug discovery screening*
12:50-13:00	**Tekon Biotech** *Advancements in acoustic droplet ejection technology for drug discovery*
13:00-13:10	**ACEA Biosciences** *Cell assay platforms: xCELLigence real-time cell analysis and NovoCyte flow cytometry*
13:10-13:20	**Life Sciences Solutions, ThermoFisher Scientific** *Life Technologies: integrate biology capability into drug discovery total solution*
Parallel session 2-1: Technology Moderators: Xuejun Li and Aimin Xu	
11:00-11:20	**Jiarui Wu** (ShanghaiTech University, China) *Protein polymorphism and personalized medicine*
11:20-11:40	**Hiroki Oguri** (Hokkaido University, Japan) *Development of a biogenetically inspired assembly line for skeletally diverse indole alkaloids*
11:40-12:00	**Chris Battershill** (Waikato University, New Zealand) *Drug leads downunder: smart discovery and development from marine sources*
12:00-12:20	**Gisela Concepcion** (University of the Philippines, Philippines) *Marine organisms: from ecological to pharmacological leads*
	Lunch break and Technology Showcase 2 (12:20-13:20)
12:30-12:40	**Waters Technologies** *Recent advancement of HDX-MS technology for protein conformation and dynamics*
12:40-12:50	**Hamamatsu Photonics** *Beyond GPCR, latest development and applications on Hamamatsu FDSS instrument*

12:50-13:00	**Hamilton** *Fast automated oligosaccharide pattern profiling of therapeutic glycoproteins*
13:00-13:10	**Seahorse Bioscience** *Application of cell metabolism real-time monitoring technology in drug screening*
13:10-13:20	**Tecan (Shanghai) Trading Co., Ltd.** *Robotics accelerate new drug discovery by Tecan*
Parallel session 3-1: Collaboration Moderators: Jiayu Liao and Siddhartha Roy	
11:00-11:20	**Xiao-Nong Zhou** (National Institute of Parasitic Diseases, CDC, China) *The challenges and research priorities to archive the roadmap of WHO NTDs control and elimination*
11:20-11:40	**David Williams** (Rush University Medical Center, USA) *Redox biology and drug development for schistosomiasis*
11:40-12:00	**Chun Guo** (Shenyang Pharmaceutical University, China) *Design, synthesis and antimalarial activity of novel artemisinin derivatives as cysteine protease falcipain-2 inhibitors*
12:00-12:20	**Brigitte Gicquel** (Institut Pasteur, France and China) *The challenges for the treatment of tuboculosis*
Plenary lectures Moderator: Peter Shepherd	
13:20-13:55	**Sunghoon Kim** (Seoul National University, Korea) *Novel drug discovery from catalytic and non-catalytic activities of aminoacyl-tRNA synthetases*
13:55-14:30	**Ronald Quinn** (Griffith University, Australia) *Fragment-based drug discovery based on a unique natural product library using FT-ICR-MS*
14:30-15:05	**Siddhartha Roy** (CSIR-Indian Institute of Chemical Biology, India) *A designed bivalent constrained peptide against melanoma*
15:05-15:20	Coffee Break
Parallel session 1-2: Innovation Moderators: Deborah Hay and Ruiping Xiao	
15:20-15:40	**Jian-Dong Jiang** (Institute of Materia Medica, Chinese Academy of Medical Sciences) *Berberine: a botanic drug for metabolic disorders*
15:40-16:00	**Aimin Xu** (The University of Hong Kong, Hong Kong S.A.R., China) *The FGF21-adiponectin axis in adipose tissues as a target for obesity-related metabolic disorders*
16:00-16:20	**Jia Li** (The National Center for Drug Screening, China) *Tissue specific PGC1 alpha transcription modulator improves metabolic syndrome in db/db mice*
16:20-16:40	**Donghai Wu** (Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences) *Brown or beige fat cells as new drug targets for the treatment of metabolic disorders*
16:40-17:00	**Jingya Li** (The National Center for Drug Screening, China) *Targeting to mitochondria function for treating metabolic diseases*
17:00-17:20	**Shihuan Kuang** (Purdue University, USA) *Regulation of white to brown adipocyte switching by MicroRNA*
17:20-17:40	**Rasmus Prætorius Clausen** (University of Copenhagen, Denmark) *Probing histone methylation and demethylation with small molecules and peptides*
17:40-18:00	**Jianping Zuo** (Shanghai Institute of Materia Medica, Chinese Academy of Sciences) *Therapeutic effects of DZ2002, a reversible SAHH inhibitor, on lupus mice via interference with TLR-mediated APC response*
18:00-18:20	**Jack Flanagan** (Maurice Wilkins Centre and University of Auckland, New Zealand) *Discovery of new inhibitors for the human steroid and prostaglandin metabolising enzyme, aldo-keto reductase 1C3*
18:20-18:40	**Zhaobing Gao** (Shanghai Institute of Materia Medica, Chinese Academy of Sciences) *PIP2 alters pharmacological selectivity for epilepsy-causing KCNQ channels*
Parallel session 2-2: Technology Moderators: Chris Battershill and Gisela Concepcion	
15:20-15:40	**Fiona Marshall** (Heptares Therapeutics, UK) *Structure based drug design directed at G protein-coupled receptors*
15:40-16:00	**Eric Xu** (Shanghai Institute of Materia Medica, Chinese Academy of Sciences) *Structural mechanisms and drug discovery of dissociated glucocorticoids*

16:00-16:20	**Jesper Lau** (Novo Nordisk A/S, Denmark) *Pharmaceutical protein and peptide engineering: from once daily to once weekly GLP-1*
16:20-16:40	**Qiang Zhao** (Shanghai Institute of Materia Medica, Chinese Academy of Sciences) *Structure and functional implications of purinergic receptor P2Y12*
16:40-17:00	**Sun Choi** (Ewha Womans University, Korea) *Identification of the allosteric communications of GPCR by agonists and structure-based design of adenosine receptor modulators*
17:00-17:20	**Chen Chen** (Sundia MediTech, China) *Revisit the CRF antagonist research after receptor crystal structure*
17:20-17:40	**Rasmus Jorgensen** (Novo Nordisk A/S, Denmark) *Using BRET to monitor receptor interactions with downstream signaling partners – examples for GLP-1 and insulin receptors*
17:40-18:00	**Yuehai Ke** (Zhejiang University School of Medicine, China) *Cell-based phenotypic screening identifies essential kinases and phosphatases targeting lung injuries and inflammation*
18:00-18:20	**Zhanfeng Cui** (University of Oxford, UK) *Development of advanced in vitro 3-D human tissue models for drug screening applications*
Parallel session 3-2: Collaboration Moderators: Camilo Colaco and Hiroki Oguri	
15:20-15:40	**Weiqing Pan** (Second Military Medical University, China) *Rational design and development of recombinant vaccine against parasite infections*
15:40-16:00	**Rosanna Peeling** (London School of Hygiene and Tropical Medicine, UK) *Innovation partnerships to accelerate diagnostic development and access*
16:00-16:20	**Wei Hu** (Fudan University, China) *Potential drug targets in Schistosoma japonicum*
16:20-16:40	**Ming-Wei Wang** (The National Center for Drug Screening, China) *Class B GPCR drug discovery: from serendipitous findings to organized efforts*
16:40-17:00	**Jiayu Liao** (University of California, Riverside, USA) *Activate glucagon-like peptide-1 receptor with small molecules*
17:00-17:20	**Palle Høy Jakobsen** (Novo Nordisk A/S, Denmark) *International collaborations for talent attraction and know-how*
17:20-17:40	**Yue-Wei Guo** (Shanghai Institute of Materia Medica, Chinese Academy of Sciences) *Recent Sino-Italian collaborative studies on the discovery of drug leads from the South China Sea marine organisms*
17:40-18:00	**Jeanette Wood** (Maurice Wilkins Centre and University of Auckland, New Zealand) *How to get large pharma companies interested in your drug discovery and development projects?*
18:00-18:20	**Yang Ye** (Shanghai Institute of Materia Medica, Chinese Academy of Sciences) *Win-win inspired complementary partnerships: SIMM international practices in the last two decades*
18:20-18:40	**Adam Podmore** (University of Auckland, New Zealand) *Drug discovery and development commercialization - the Auckland UniServices story*
19:00-21:00	Welcome dinner at the Parkyard Hotel (by invitation only)
End of day 1	

Friday, March 14, 2014

Plenary lectures Moderator: Xiao-Nong Zhou	
8:15-8:50	**Bill Denny** (Maurice Wilkins Centre and University of Auckland, New Zealand) *Drug development for neglected diseases: persistent tuberculosis and leishmaniasis*
8:50-9:25	**Motonari Uesugi** (Kyoto University, Japan) *Small molecules that block fat synthesis*
9:25-10:00	**Cheryl Arrowsmith** (University of Toronto, Canada) *Open access chemical probes for target discovery and validation of epigenetic regulators*
10:00-10:15	Coffee Break
Parallel session 1-3: Innovation Moderators: Sun Choi and Rasmus Jorgensen	
10:15-10:35	**Daniel Hoyer** (The University of Melbourne, Australia) *Neuropsychiatric disorders: target identification, validation and engagement*
10:35-10:55	**Richard D. Ye** (Shanghai Jiaotong University, China) *Receptors for amyloid proteins as potential targets for anti-inflammatory therapy*
10:55-11:15	**Takayoshi Suzuki** (Kyoto Prefectural University of Medicine, Japan) *Design, synthesis, and biological activity of lysine-specific demethylase 1 inhibitors*
11:15-11:35	**Yizhun Zhu** (Fudan University, China) *Discovery of novel compounds from Chinese herbs for heart and brain diseases: from bench to bedside*
11:35-11:55	**Peter Shepherd** (Maurice Wilkins Centre and University of Auckland, New Zealand) *Targeting kinases in cancer*
11:55-12:15	**Hongxi Xu** (Shanghai University of Traditional Chinese Medicine, China) *Natural compound oblongifolin C inhibits autophagic flux and enhances antitumor efficacy of nutrient deprivation*
Parallel session 2-3: Technology Moderators: Young-Tae Chang and David Williams	
10:15-10:35	**Hualiang Jiang** (Shanghai Institute of Materia Medica, Chinese Academy of Sciences) *Kinetics of drug-target binding*
10:35-10:55	**Alan Davidson** (Maurice Wilkins Centre and University of Auckland, New Zealand) *Using human iPS cells to make model systems for drug discovery*
10:55-11:15	**Qiang Yu** (Shanghai Institute of Materia Medica, Chinese Academy of Sciences) *Tyrosine kinase signaling-based personalized diagnosis and treatment of cancer*
11:15-11:35	**Junko Ohkanda** (Institute for Chemical Research, Kyoto University, Japan) *Rational design of fusicoccin-based fluorescent probes for detecting 14-3-3 complexes*
11:35-11:55	**Weiliang Zhu** (Shanghai Institute of Materia Medica, Chinese Academy of Sciences) *Simulating large scale conformation change for understanding protein function*
11:55-12:15	**Seung Bum Park** (Seoul National University, Korea) *FITGE-based target identification for the connection of rational drug discovery with phenotypic screening*
Parallel session 4-1: Postgraduates' Podium (10:15-12:15) Organizer: Yue-Ting Chen Evaluation panel: Ke Ding, Brigitte Gicquel, Jesper Lau, Takayoshi Suzuki and Xiao Xu	
10:15-10:27	**Dakai Chen** (The Chinese National Compound Library, China) *Identification and characterization of a novo small molecule AMPK allosteric activator that orally exerts beneficial effects on diabetic ob/ob mice*
10:27-10:39	**Minghua Cui** (Ewha Womans University, Korea) *Design, synthesis and molecular modeling study of novel anti-malarial Pf-calpain inhibitors*
10:39-10:51	**Yunjun Ge** (The Chinese National Compound Library, China) *The putative signal peptide of glucagon-like peptide-1 receptor is not required for establishing its functionality*
10:51-11:03	**Xin Li** (Peking University, China) *A natural product derivative AD-20 inhibits cancer cell migration by suppressing the expression of Neuropilin-1*

11:03-11:15	**Hongchuan Liu** (The Second Military Medical University, China) *Chemical constituents from Rabdosia japonica and their cytotoxicity and anti-HBV activities*
11:15-11:27	**Zhiqing Liu** (Shanghai Institute of Materia Medica, Chinese Academy of Sciences) *Novel 2,4-diarylaminopyrimidine analogues showing potent c-Met/ALK multikinase inhibitory activities*
11:27-11:39	**Xinxiu Xu** (The National Center for Drug Screening, China) *Hyperosmosis facilitates mouse somatic cell reprogramming*
11:39-11:51	**Jianpeng Yin** (The National Center for Drug Screening, China) *Design and synthesis of paracaseolide A analogues as selective protein tyrosine phosphatase 1B inhibitors*
11:51-12:03	**Lun Zhang** (Shanghai Institute of Materia Medica, Chinese Academy of Sciences) *Functional role of conserved HxD-histidine in the catalytic core of protein kinases*
12:03-12:15	**Yueming Zheng** (Shanghai Institute of Materia Medica, Chinese Academy of Sciences) *Hexachlorophene is a potent KCNQ1/KCNE1 potassium channel activator which rescues LQTs mutants*
Parallel session 5-1: Roundtable Discussion (10:15-12:15) *How to commercialize your innovation?* Organizers: Gang Liu and Jeanette Wood	
Lunch break and Technology Showcase 3 (12:15-13:15)	
12:20-12:40	**PerkinElmer** *Up-to-date imaging technologies in drug discovery*
12:40-13:00	**ThermoFisher Scientific** *New solution integration in drug discovery from ThermoFisher*
Plenary lectures Moderator: Xin Xie	
13:15-14:00	**Kurt Wüthrich** (Swiss Federal Institute of Technology in Zurich, Switzerland) *Rational structure-based drug design – contributions from NMR*
14:00-14:45	**Barry Potter** (University of Bath, UK) *Steroid sulfatase inhibitors: from concept to clinical trials*
14:45-15:00	**Coffee Break**
Parallel session 1-4: Innovation Moderators: Rasmus Prætorius Clausen and Fiona Marshall	
15:00-15:20	**Xuejun Li** (Peking University Health Science Center, China) *Autophagy mediates the cytoprotective mechanism of polyphenols*
15:20-15:40	**Ho Jeong Kwon** (Yonsei University, Korea) *Mitochondrial UQCRB and its inhibitors*
15:40-16:00	**Jianmin Yue** (Shanghai Institute of Materia Medica, Chinese Academy of Sciences) *Discovery of structurally diverse and biologically important components from plant sources*
16:00-16:20	**Xiao Xu** (Hangzhou High-throughput Drug Screening Center, China) *Precision targeted therapy for lung cancer: an irreversible wild-type sparing inhibitor of acquired EGFR T790M gatekeeper mutation*
16:20-16:40	**Ke Ding** (Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences) *Targeting the undruggable target: identification of the first class of estrogen-related receptor a agonists*
16:40-17:00	**Hong Liu** (Shanghai Institute of Materia Medica, Chinese Academy of Sciences) *Structural modification and bioactivity evaluation of multi-targeted tetrahydroprotoberberine derivatives (THPBs)*
17:00-17:20	**Deyong Ye** (Fudan University, China) *The discovery of the first-class inhibitors of sphingomyelin synthase*
17:20-17:40	**Yang Li** (Shanghai Institute of Materia Medica, Chinese Academy of Sciences) *Natural products bring out new generation of antipsychotic drugs*
Parallel session 2-4: Technology Moderators: Ho Jeong Kwon and Junko Ohkanda	
15:00-15:20	**De-An Guo** (Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China) *Pharmacological tools for the development of traditional Chinese medicine*

15:20-15:40	**Young-Tae Chang** (National University of Singapore, Singapore) *Bioimaging probe development and drug screening*
15:40-16:00	**Camilo Colaco** (ImmunoBiology Ltd. UK) *Vaccine platforms targeting dendritic cells*
16:00-16:20	**Xiaobo Wang** (ACEA Biosciences, Inc., USA) *Real-time cell analysis: how a label-fee technology is transforming cell biology and drug discovery*
16:20-16:40	**Henry Ji** (Sorrento Therapeutics, Inc.,USA) *Human therapeutic antibodies and antibody-drug conjugate (ADC) technology*
16:40-17:00	**Tian Xia** (Huazhong University of Science and Technology, China) *Ultra high-throughput yeast chemical genomics for discovering mechanisms of bioactivity*
17:00-17:20	**Yan Chang** (National Shanghai Center for New Drug Safety Evaluation and Research, China) *Progress on regulatory genetic toxicology*
17:20-17:40	**Ti He** (Hangzhou Adicon Clinical Laboratories, Inc., China) *The challenges and solutions of companion diagnostics development during oncology trials*
Parallel session 5-2: Roundtable Discussion (15:00-17:40) *How to build a win-win R&D partnership?* Organizers: Palle Høy Jakobsen and Adam Podmore	
Parallel session 4-2: Young Investigators' Forum (15:00-17:40) Organizer: Yi Zang Evaluation panel: Chen Chen, Jack Flanagan, Seung Bum Park, Rosanna Peeling and Beili Wu	
15:00-15:15	**Yue-Ting Chen** (The National Center for Drug Screening, China) *Design, synthesis, SAR and mechanistic studies of small molecules with spiro skeleton that promote induced pluripotent stem cells generation*
15:15-15:30	**Jiejie Deng** (The National Center for Drug Screening, China) *Label-free monitoring of T cell activation by the impedance-based xCELLigence system*
15:30-15:45	**Chunyong Ding** (Shanghai Institute of Materia Medica, Chinese Academy of Sciences) *Design, synthesis and anticancer activity of novel oridonin derivatives*
15:45-16:00	**Guohuang Fan** (GlaxoSmithKline R&D Shanghai, China) *Phenotypic screening of M1/M2 modulators for neurodegenerative disorders*
16:00-16:15	**Xun Huang** (Shanghai Institute of Materia Medica, Chinese Academy of Sciences) *JG6, a novel marine-derived oligosaccharide, suppresses breast cancer metastasis via binding to cofilin*
16:15-16:30	**Yoonji Lee** (Ewha Womans University, Korea) *Structural studies of transient receptor potential vanilloid type 1 (TRPV1) and the binding mode analysis of its modulators*
16:30-16:45	**Tao Meng** (Shanghai Institute of Materia Medica, Chinese Academy of Sciences) *The discovery and optimization of 4,5-diarylisoxazole as ATP-competitive inhibitors of pyruvate dehydrogenase kinases*
16:45-17:00	**Hua Zhang** (Shanghai Institute of Materia Medica, Chinese Academy of Sciences) *A biogenesis inspired example in the discovery of new bioactive molecules from a Chinese medicinal plant*
17:00-17:15	**Li-Na Zhang** (The National Center for Drug Screening, China) *Brown remodelling of white adipose tissue by small molecules*
17:30-17:40	Announcement of oral presentation prizes in the name of TiPS
Closing ceremony in the main hall	
17:40-17:50	Closing remarks: **Professor Peter Shepherd** Maurice Wilkins Centre and University of Auckland, New Zealand
18:00	Departure to the Culture Square by coach at the main entrance of Parkyard Hotel
19:15	Youth Inspirational Musical: ***Nasirdin Afandi*** entertained by Shanghai Municipal Government (by invitation only)
22:00	**End of day 2** (return to Parkyard Hotel by coach)

三月宣言

我们，来自全球 17 个国家和地区、从事新药发现与开发的科学家、企业家、经理人和研究生相聚浦东张江，凭借 2014 年皇后镇分子生物学（上海）会议的互动平台，围绕“ 创新、技术与合作 ”这三大主题，介绍研究发现，交流专业信息，推广技术成果，切磋合作机遇，共商创新大计。

我们认识到救死扶伤，提高健康水平和推动社会发展是人类的共同使命。在经济日趋全球化的今天，在生命科学领域的创新活动比任何时候都更需要身居世界各地“ 利益攸关者 ”的参与、贡献和分享。这种渴望合作的意愿超越国界、种族与文化差异，成为我们携手开拓的崇高理念。

我们所追求的愿景将在充分保障各“ 利益攸关者 ”自主知识产权和完全自愿的原则指导下，通过资源共享、人才共享、技术共享、信息共享、知识共享、经验共享、设备共享和成果共享等八种形式予以体现。这种共享机制不仅具有服务社会的公益性而且也为成果的产业化创造契机。

我们将以双边、多边和互利多赢的方式建立各类合作关系，利用浦东新区现有的人才、资金、政策及地理优势，以国家化合物样品库作为资源纽带、皇后镇分子生物学（上海）会议为沟通机制，创建“ 张江国际合作中心 ”，将其“ 药谷 ”打造成世界一流的药物与诊断技术创新平台。

March Manifesto

We scientists, entrepreneurs, managers and graduates from 17 different countries and regions across the world are gathering in Zhangjiang, Pudong to introduce scientific findings, exchange research information, promote novel technologies, discuss collaboration opportunities and converse on innovation plans utilizing the 2014 Queenstown Molecular Biology Meetings in Shanghai as a communication platform.

We recognize that healing the sick, helping the dying, improving welfare and health, and accelerating social development are common missions of mankind. With a continuously globalizing economy, the participation in, contribution to and sharing with innovative activities in the life sciences by stakeholders from every corner of the world has become more crucial than ever. Such a desire for cooperation is deeply rooted in our hearts irrespective of national border, race and culture, thereby becoming a noble cause for us to jointly pursue.

Under the principle of complete free-will and full protection of stakeholders' intellectual property rights, such vision is expected to be materialized by the sharing of discovery resources, human capital, technical capabilities, up-to-date information, scientific knowledge, research experiences, laboratory facilities and economic benefits. This unique mechanism of partnership not only satisfies the public interest by providing services to society but also reaps our endeavors a plethora of commercialization opportunities.

We intend to set up various types of collaborative efforts of bilateral, multi-lateral, mutual beneficial and "all-win" nature. We shall maximize existing strengths in Pudong relative to talent pool, available funds, preferential policies and geographic location, to establish "Zhangjiang International Collaboration Center", using the Chinese National Compound Library as a resource link and the Queenstown Molecular Biology (Shanghai) Meetings as a communication channel, with an ultimate goal of making the Zhangjiang "Pharma Valley" a world-class innovation launchpad for drug discovery and diagnostic technologies.

Manifeste de Mars

Nous, scientifiques, industriels, managers, et étudiants de 17 pays et régions du monde, sommes rassemblés à Zhangjiang, Pudong, pour présenter nos travaux scientifiques, parler de nos recherches, promouvoir les nouvelles technologies, discuter des opportunités de collaborations et des échanges concernant l'innovation en utilisant la réunion de Biologie Moléculaire de 2014 de Queenstown à Shanghai comme plateforme de communication.

Nous considérons que guérir les malades et venir en aide aux personnes en fin de vie, améliorer le bien-être et la santé, et accélérer le développement sociétal sont des missions communes à tout le genre humain. Avec une globalisation continuelle de l'économie, la participation et la contribution au partage des activités innovantes dans le domaine des sciences du vivant par les acteurs du monde entier sont devenues plus cruciales que jamais. Un tel désir de coopération est profondément enraciné dans nos cœurs, indépendamment des frontières, des populations et des cultures, devenant ainsi pour nous une cause noble à poursuivre ensemble.

Fondée sur le principe de libre arbitre et de complète protection des droits de propriété intellectuelle des participants, nous espérons qu'une telle vision se matérialise par le partage des ressources des découvertes, du capital humain, des capacités techniques, des dernières découvertes en date, des connaissances scientifiques, des expérimentations, des espaces de laboratoires et des bénéfices économiques. Cette méthode unique de partenariat ne satisfait pas seulement l' intérêt du public en offrant des services à la société, mais également en ouvrant la voie à de nombreuses opportunités de commercialisation, fruits de nos efforts communs.

Nous avons pour but de mettre en place plusieurs types de collaborations bilatérales et multilatérales, à bénéfice mutuel et dans une optique "gagnant-gagnant". Nous maximiseront les forces existantes à Pudong quant au vivier de talents, aux fonds disponibles, aux politiques et aux différentes régions géographiques, afin d'établir le "Centre de Partenariat International de Zhangjiang". Pour cela, nous utiliserons la Banque Nationale Chinoise de Composés comme un lien et les réunions de Biologie Moléculaires de Queenstown à Shanghai comme un circuit de communication, avec pour but ultime de faire de la "Vallée Pharmaceutique" de Zhangjiang une aire de développement innovant, et reconnue mondialement, pour la découverte de nouveaux médicaments et de nouvelles technologies diagnostiques.

三月宣言

私たち、世界17の異なる国と地域から来た科学者、企業家、経営者と大学院生は２０１４年上海でのクイーンズタウンの分子生物学会議を活用し、そのコミュニケーションプラットフォームとして、「革新・技術・協力」この３大テーマをめぐり、互いの科学的発見を紹介、研究情報を交換、また新しい技術を促進、さらには共同での作業の機会について検討し、イノベーションプランを対話するために浦東張江に集まっています。

私たちは、病気の人々を治し、死に瀕する人々を救い、福祉および健康状態を改善し、社会の発展を推進することが人類共通の使命と認識しています。この日々グローバル化する経済の中で、世界各地から「ステークホルダー（利益の関わる者）」による生命科学の領域での革新活動に参加、貢献、共有をすることはこれまでになく重要になっています。このような国境、人種と文化を越えた私たちの心に深く根付いている協力への渇望は、共に私たちが追及するべき崇高な理念になります。

ステークホルダーの知的所有権の完全な自由意志と十分な保護の原理の下では、資源、人材、技術力、最新情報、科学知識、研究経験、実験室施設および経済的便益の共有によってそのようなビジョンが実現されると予想されます。協力のこのユニークなメカニズムは社会に対して提供する貢献によって公益を満たすだけでなく、私たちにあり余るほどの商業化機会をも創造することでしょう。

私たちは両側面、それ以上の多側面の相互利益と勝利のための様々なタイプの協力体制を設立するつもりです。私たちは、創薬および診断の技術のために張江「Pharma Valley」を世界一流のイノベーションの発射台にするという究極のゴールと共に、中国の国家化合物ライブラリーを資源リンクとして、また、クイーンズタウン分子生物学（上海）会議を通信チャンネルとして、「張江国際協力センター」を確立するために人材、資金、優先的政策および地理的位置に関して浦東新区での既存の強さを最大限に発揮します。

3월선언

전세계 17개 국가와 지역에서 신약개발에 종사하는 과학자, 기업가, 경영자와 대학원생들이 Zhangjiang, Pudong에 모여 "혁신과 기술 및 협력"을 주제로 하는 "2014 Queenstown Molecular Biology Meetings in Shanghai"에서 연구성과와 정보를 교류할 것입니다.

질병에 대한 치료 및 건강과 복지 수준에 대한 향상은 인류 공통의 과제입니다. 경제가 나날이 발전하고 있는 현재, 생명과학 영역에서의 혁신 활동은 그 어느 때보다 세계 각지의 이해관계자들의 참여 및 공헌과 공유가 필요한 시점입니다. 이런 협력에 대한 바램은 국경과 인종, 문화적 차이를 초월하여 우리 모두가 함께 추구하는 고귀한 이유가 되었습니다.

이러한 비전은 이해관계자들의 지식재산권을 보장하고 자유의지의 원칙하에 자원, 인재, 기술, 정보, 지식, 경험, 시설과 성과를 공유함으로써 실현될 것입니다. 이와 같이 독특한 동반자적 체계는 사회의 공익성에 기여를 할 뿐만 아니라 성과의 산업화에도 좋은 기회를 만들어 줄 것입니다.

우리는 상호적, 다각적, 상호간 이익을 얻는 협력 방식으로 Pudong신지역이 현재 보류하고 있는 인재, 자금, 정책과 지리적인 이점을 이용하고 중국 국가 화합물 라이브러리(Chinese National Compound Library)를 연결고리 삼아, Queenstown Molecular Biology (Shanghai) Meetings를 교류 경로로 하여 "Zhangjiang 국제협력중심"을 만들 것입니다. 그리하여 궁극적으로 이러한 Zhangjiang "Pharma Valley"를 약물과 진단기술에 있어 세계적 수준의 혁신의 발판으로 삼으려 합니다.

三月宣言

我們，來自全球 17 個國家和地區、從事新藥發現與開發的科學家、企業家、經理人和研究生相聚浦東張江，憑借 2014 年皇後鎮分子生物學（上海）會議的互動平臺，圍繞“創新、技術與合作”這三大主題，介紹研究發現，交流專業信息，推廣技術成果，切磋合作機遇，共商創新大計。

我們認識到救死扶傷，提高健康水平和推動社會發展是人類的共同使命。在經濟日趨全球化的今天，在生命科學領域的創新活動比任何時候都更需要身居世界各地“利益攸關者”的參與、貢獻和分享。這種渴望合作的意願超越國界、種族與文化差異，成為我們攜手開拓的崇高理念。

我們所追求的願景將在充分保障各“利益攸關者”自主知識產權和完全自願的原則指導下，通過資源共享、人才共享、技術共享、信息共享、知識共享、經驗共享、設備共享和成果共享等八種形式予以體現。這種共享機制不僅具有服務社會的公益性而且也為成果的產業化創造契機。

我們將以雙邊、多邊和互利多贏的方式建立各類合作關系，利用浦東新區現有的人才、資金、政策及地理優勢，以國家化合物樣品庫作為資源紐帶、皇後鎮分子生物學（上海）會議為溝通機制，創建“張江國際合作中心”，將其“藥谷”打造成世界壹流的藥物與診斷技術創新平臺。

Biography

Cheryl H. Arrowsmith, Ph.D.

Title & Affiliation:

Chief Scientist, SGC-Toronto
Senior Scientist, Princess Margaret Cancer Centre
Professor, Department of Medical Biophysics, University of Toronto
Canada Research Chair in Structural Genomics

E-mail address: carrow@uhnres.utoronto.ca

Telephone: 416-946-0881

Biography:

Cheryl Arrowsmith is a Senior Scientist at Princess Margaret Cancer Centre and Professor in the Department of Medical Biophysics at the University of Toronto, where she holds a Canada Research Chair in Structural Genomics. She received a Ph.D. in chemistry from the University of Toronto and carried out postdoctoral research at Stanford University in the area of protein NMR spectroscopy. Dr. Arrowsmith's research focuses on the use of structural and chemical biology methods for understanding the structure-function relationships of proteins and their role in cancer. Dr. Arrowsmith is the Chief Scientist of the Toronto Node of the Structural Genomics Consortium (SGC), a European-Canadian public-private partnership that supports the discovery of new medicines through open access research.

Notes:

Chris Battershill, Ph.D.

Title & Affiliation:

Professor and Chair of Coastal Science and Director of the Coastal Field Centre, Tauranga
University of Waikato, New Zealand

E-mail address: cbatters@waikato.ac.nz

Telephone: 64-75570481 Fax: 64-75794054

Biography:

Chris Battershill became inaugural Professor and Chair of Coastal Science, University of Waikato in January 2011. Prior to that, he was Leader of the Marine Resources and Biodiversity Teams at the Australian Institute of Marine Science (AIMS) for twelve years.

He completed his Ph.D. at Auckland University in 1986 then undertook a 3-year Research Fellowship funded through the National Cancer Institute (US) based at the University of Canterbury, leading the New Zealand shallow water collection program for drug discovery. He did postdoctoral work in Australia and then worked in New Zealand for 11 years focusing on sustainability of marine resource use, building capacity in research associated with marine drug discovery.

Projects are current from the high tropics to the Antarctic and throughout New Zealand. Of note in recent times, has been working associated with advancing a number of FDA registered anti-tumour active drug leads from New Zealand and Australia (including the new drug Halaven®), through solving supply issues of the lead marine natural product. Publications include co-authorship of 3 books and over 100 international peer reviewed research publications. He is an Adjunct Professor at the University of Western Australia and James Cook University.

Notes:

Yan Chang, Ph.D.



Title & Affiliation:

Deputy Director, National Shanghai Center for New Drug Safety Evaluation and Research, China

E-mail address: ychang@ncdser.com

Telephone: 86-21-50800333x208

Biography:

Dr. Yan Chang, Deputy Director of National Shanghai Center for New Drug Safety Evaluation and Research. She obtained B.A. and M.S. degrees from Zhejiang Medical University and a Ph.D. from Shanghai Institute of Pharmaceutical Industry. Thereafter, she was engaged in genetic and reproductive toxicology research. She serves as a Member of Chinese SFDA CDE External Review Panel and SFDA GLP Inspector. In 2009, she became an AAALAC ad hoc specialist. She also serves as an active member of Chinese Pharmacological Society and Chinese Toxicological Society, a committee member of Committee of Reproductive Toxicology of Chinese Toxicological Society and Toxicology Committee of Shanghai Society of Pharmacology. In 2011, she obtained National Outstanding Young Scientist Award from Chinese Society of Toxicology. In 2013, she was named by Shanghai Women's Union as Shanghai Woman Pace-setter.

Notes:

Young-Tae Chang, Ph.D.

Title & Affiliation:

Professor of Chemistry Department, NUS, Singapore

Head, Laboratory of Bioimaging Probe Development, SBIC,

*A*STAR, Singapore*

E-mail address: chmcyt@nus.edu.sg

Telephone: 65-6516-6774 Fax: 65-6779-1691

Biography:

Young-Tae Chang was born in Busan, Korea in 1968. He studied chemistry in Pohang University of Science and Technology (POSTECH, Korea) and received his B.S. in 1991. After one and a half years of army service in Korea, he started his graduate study at POSTECH and received a Ph.D. in 1997 under the supervision of Prof. Sung-Kee Chung, working on the divergent synthesis of all possible regioisomers of myo-inositol phosphates. He did his postdoctoral work with Prof. Peter Schultz at UC Berkeley and The Scripps Research Institute. In 2000, he was appointed as an assistant professor at New York University and promoted to associated professor in 2005. He received the NSF Career Award in 2005 and his research interests have been chemical genetics, molecular evolution, and artificial tongues. In September, 2007, he moved to National University of Singapore and Singapore Bioimaging Consortium. He is a full Professor of Chemistry and leader of Medicinal Chemistry Program of NUS, and Laboratory Head of Bioimaging Probe Development at SBIC, Biopolis. He published more than 200 scientific papers, 3 books and filed 30 patents so far.

Notes:

Chen Chen, Ph.D.

Title & Affiliation:

CEO, Sundia MediTech Company, China

E-mail address: chenchen@sundia.com

Telephone: 86-21-51098642x117 Fax: 86-21-51903509

Biography:

Dr. Chen has a Ph.D. in Organic Chemistry from Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, and obtained his postdoctoral training at Texas A&M University, with Nobel Laureate, Professor Sir Derek H.R. Barton, at the University of Illinois, Chicago. He spent 15 years at Neurocrine as Scientist to Senior Director of Medicinal Chemistry. In his research and management positions, Dr. Chen has achieved many outstanding scientific and industrial accomplishments, including the development of the very first CRF antagonist NBI-30775 into clinical studies, and two small molecule antagonists, NBI-42902 and elagolix, of the GnRH receptor, and the later one is currently in phase III clinical trials. Dr. Chen has extensive experience in CNS drug research and in GPCRs as drug targets. His research interests extend to clinic pharmacokinetics of small molecules.

Dr. Chen has served as Sundia's CEO since 2012. He has published about 130 scientific papers in peer-reviewed journals and written numerous review articles on the topics of drug discovery and medicinal chemistry. He has been invited to give presentations in numerous scientific conferences such as the Gorden Research Conference of Medicinal Chemistry and the ACS National Meeting.

Notes:

Sun Choi, Ph.D.

Title & Affiliation:

National Leading Research Laboratory (NLRL) of Molecular Modeling and Drug Design,College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Korea

E-mail address: sunchoi@ewha.ac.kr

Telephone: 82-2-3277-4503 Fax: 82-2-3277-2851

Biography:

Dr. Sun Choi is a professor at the College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Korea. After obtained her Ph.D. in Medicinal Chemistry from the State University of New York at Buffalo, USA, she joined Prof. Richard B. Silverman's laboratory in Department of Chemistry and Drug Discovery Program at Northwestern University, Evanston, IL, USA. From 2001 to 2005, she worked as a molecular modeler and computational chemist at the molecular design group in Tripos, Inc., St. Louis, MO, USA. Then, she joined Ewha Womans Univeristy as a faculty member, where she has been an associate professor since 2011. Her research focuses on the state-of-the-art technologies of computer-aided drug design, cheminformatics, computational medicinal chemistry, and biomolecular simulations. Based on these computational methods, she has been conducting multiple research projects targeting therapeutically important enzymes, GPCRs, and ion channels. Active interdisciplinary collaborations are on-going for drug discovery in various diseases such as cancer, viral infections, pain, cardiovascular disease, osteoporosis, etc. Since 2011, her laboratory has been designated as the National Leading Research Laboratory (NLRL) by the Korean government.

Notes:

Rasmus Prætorius Clausen, Ph.D.

Title & Affiliation:

Rasmus Prætorius Clausen, M.Sc., Ph.D.
Associate Professor, Department of Drug Design and Pharmacology, Faculty of Health and Medical Siences, University of Copenhagen, Denmark

E-mail address: rac@sund.ku.dk

Telephone: 45-35336566

Biography:

Rasmus Prætorius Clausen obtained his M.Sc. in Chemistry and Cell Biology from University of Southern Denmark (Odense) and did thesis work with Dr. Jan Becher. He took his Ph.D. from Aarhus University with Prof. Mikael Bols. Thereafter, he was shortly employed as a medicinal chemist at Lundbeck A/S, and then joined the research group of Prof. Povl Krogsgaard-Larsen at Department of Medicinal Chemistry at the former Royal Danish School of Pharmacology (now part of University of Copenhagen). He is now Associate Professor and his research in neuromedicinal chemistry has been focused on developing selective glutamate receptor ligands, GABA transport inhibitors and GHB tool compounds. Lately he also started research on developing inhibitors for histone methyltransferases and demethylases. He was treasurer and executive committee member in the European Federation of Medicinal Chemistry (EFMC) from 2006 to 2012.

Notes:

Camilo Colaco, Ph.D.

Title & Affiliation:

Chief Scientist, ImmunoBiology Ltd, Babraham Research Campus, Babraham, Cambridge CB22 3AT, UK

E-mail address: camilo.colaco@immunobiology.co.uk

Telephone: 44-1223-496116 Fax: 44-1223-496011

Biography:

Having graduated from the University of London with a first class (Honors) degree in Biochemistry, Dr. Colaco did his Ph.D. at the NIMR in Mill Hill. After an AHA-BHF fellowship at CALTECH in Pasadena, he returned to the ICRF Laboratories before taking up a lectureship at Cambridge via a Royal Society fellowship at EMBL in Heidelberg. After setting up the first molecular biology laboratory at the Medical School in Cambridge he moved from academic to translational science in 1990, founding the Quadrant Research Foundation to develop technologies for the conversion of fragile biologicals into stable formats that do not need refrigeration. These were commercialized by Quadrant Healthcare PLC, which was listed on the LSE and subsequently purchased by the US biotech Elan Inc. In 2000, based on his seminal identification of the dendritic cell as the key integrator of innate and acquired immunity, Dr. Colaco started ImmunoBiology Ltd to develop the next generation of vaccines for infectious diseases and cancer.

Notes:

Gisela P. Concepcion, Ph.D.

Title & Affiliation:

Vice President for Academic Affairs, University of the Philippines System
Professor, The Marine Science Institute, University of the Philippines, Diliman, Philippines

E-mail address: gpconcepcion@up.edu.ph

Telephone: 63-2-926-4736 Fax: 63-2-929-3540

Biography:

Gisela P. Concepcion is a professor at the Marine Science Institute (MSI) of the University of the Philippines (UP) in Diliman, Quezon City. She obtained her Ph.D. in Chemistry from the University of the Philippines in 1995. Her dissertation on anticancer marine compounds, known as adociaquinones from a Philippine Xestospongia sp. sponge and bistratamides from an ascidian Lissoclinum bistratum associated with the cyanobacterial Prochloron symbiont, was pursued under the guidance of Dr. Chris M. Ireland of the University of Utah. This led to their long-term collaboration funded under the US NCI NCDDG "Anticancer Agents from Unique Natural Products Sources" program. Subsequently, Dr. Concepcion collaborated with Dr. Baldomero M. Olivera of the University of Utah on neuroactive peptides from venomous marine Conoidean snails under the Philippine government-funded PharmaSeas program. Currently, she is the associate program leader in the Philippines of the US NIH ICBG Philippine Mollusk Symbiont program on neuroactive and antimicrobial compounds from bacterial symbionts of mollusks, which is led by Dr. Margo Haygood of Oregon Health & Science University. In 2006, Dr. Concepcion led a campaign to obtain more government funding for science and technology in the Philippines. This led to the construction of the National Science Complex in UP Diliman. Currently, she is serving as the Vice President for Academic Affairs of the University of the Philippines System.

Notes:

Garth Cooper, Ph.D.

Title & Affiliation:

Garth Cooper, DPhil (Oxon), MBChB, FRCPA, FRSNZ, FMedSci
Professor in Discovery and Experimental Medicine, Institute of Human Development, The University of Manchester, UK

E-mail address: garth.cooper@manchester.ac.uk;g.cooper@auckland.ac.nz

Telephone: 44-161-701-0241 Fax: 44-161-701-0241

Biography:

Garth Cooper is Professor of Discovery and Experimental Medicine at the University of Manchester, where he directs the Centre for Advanced Discovery and Experimental Therapeutics (CADET). He is Visiting Professor in Pharmacology (Drug Discovery and Experimental Therapeutics) at the University of Oxford, and Professor in Biochemistry at the University of Auckland, and currently leads research groups in Manchester and Auckland.

Professor Cooper undertook doctoral studies at the University of Oxford (1986-1989), discovering amylin and inventing amylin-based therapy for diabetes (FDA-registered 2005). He develops rigorous molecular descriptions of the pathogenesis of diabetes/complications, and has strong interests in proof-of-principle clinical studies and developing new therapies for diabetes and its complications.

In 1987 Prof. Cooper became the Founder and sole founding scientist of Amylin Pharmaceuticals, Inc., having discovered/invented its core technologies, and served as its Founding Chief Technical Officer until 1991. Prof Cooper is also active in developing intellectual property positions related to his research and has been awarded numerous international patents.

Notes:

Zhanfeng Cui, Ph.D.

Title & Affiliation:

Zhanfeng Cui, Ph.D., D.Sc., FIChemE, FREng
Donald Pollock Professor of Chemical Engineering and Director, Oxford Centre for Tissue Engineering and Bioprocessing, Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, UK

E-mail address: zhanfeng.cui@eng.ox.ac.uk

Telephone: 44-1865-617693

Biography:

Professor Zhanfeng Cui is the Donald Pollock Professor of Chemical Engineering, University of Oxford since the Chair was established in 2000. He is the founding Director of the Oxford Centre for Tissue Engineering and Bioprocessing (OCTEB). He was educated in China and got his B.Sc. from Inner Mongolia University of Technology (1982) and M.Sc. (1984) and Ph.D. (1987) from Dalian University of Technology. After a postdoctoral experience in Strathclyde University in Scotland, he joined Edinburgh University as a Lecturer in Chemical Engineering (1991). He then held academic appointments at Oxford Engineering Science Department as University Lecturer (1994-1998) and Reader (1999-2000). He was a Visiting Professor of Georgia Institute of Technology, USA (1999), the Brown Intertec Visiting Professor to University of Minnesota, USA (2004), and a Chang-Jiang Visiting Professor to Dalian University of Technology, China (2005-2009). He is a Chartered Engineer, a Chartered Scientist and a Fellow of the Institution of Chemical Engineers. In 2009 he was awarded a Doctor of Science (D.Sc.) by Oxford University to recognise his research achievements. He was elected to a Fellow of the Royal Academy of Engineering, UK, in 2013.

Notes:

Alan Davidson, Ph.D.



Title & Affiliation:

Associate Professor, Department of Molecular Medicine and Pathology, The University of Auckland, Auckland, New Zealand

E-mail address: a.davidson@auckland.ac.nz

Telephone: 64-9-923-6764

Biography:

Dr. Alan Davidson is Associate Professor in the Department of Molecular Medicine and Pathology in the School of Medical Sciences at The University of Auckland. He received a B.Sc. (Honors) and a Ph.D. from The University of Auckland and did his postdoctoral training at Children's Hospital/Harvard Medical School in Boston, USA. In 2005, Dr. Davidson started his own research program in the Centre for Regenerative Medicine at the Massachusetts General Hospital/Harvard Medical School before being awarded the Rutherford Distinguished Fellowship from the Rutherford Foundation (New Zealand) and returning to New Zealand in 2010. He is internationally recognized for his research in the fields of embryonic kidney formation and renal regeneration using zebrafish. More recently, Dr. Davidson's laboratory has begun working with human induced pluripotent stem cells and has developed methods to generate proximal tubule epithelial cells for disease modelling and drug toxicity screening.

Notes:

Bill Denny, Ph.D.

Title & Affiliation:

Co-Director, the Auckland Cancer Society Research Centre
Principal Investigator, Maurice Wilkins Centre, The University of Auckland

E-mail address: b.denny@auckland.ac.nz

Telephone: 64-9-923-6144 Fax: 64-9-373-7502

Biography:

Bill Denny is Co-Director of the Auckland Cancer Society Research Centre and a Principal Investigator in the Maurice Wilkins Centre, The University of Auckland. He was trained as a chemist at Auckland and Oxford Universities, and is a past-President of the NZ Institute of Chemistry and the NZ Society for Oncology. Awards include the Rutherford Medal of the Royal Society of NZ (1995), the Adrien Albert Medal of the UK Royal Society of Chemistry (2005), the Albert Lectureship of the Royal Australian Chemical Institute (2006), the NZBio Biotechnologist of the Year (2007), the University of Auckland Commercialisation Medal (2012) and the 2014 Medicinal Chemistry Award of the American Chemical Society. He has led or been closely involved in the design and development of 14 drugs brought to or approaching clinical trials for cancer and infectious diseases, and is a scientific co-founder of the companies Proacta Inc. (hypoxia-activated prodrugs) and Pathway Therapeutics (kinase inhibitors).

Notes:

Ke Ding, Ph.D.

Title & Affiliation:

Professor of Medicinal Chemistry,
Associate Director, Chemical Biology Department, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, China

E-mail address: ding_ke@gibh.ac.cn

Telephone: 86-20-32015276

Biography:

Dr. Ke Ding got his Ph.D. degree from Fudan University in 2001. After 3-year postdoctoral training in the University of Michigan, Ann Arbor, he was appointed as a research investigator in 2005. Dr. Ding was appointed as Professor and Deputy Director of Chemical Biology Institute in Guangzhou Institutes of Biomedicine and Health, CAS, in 2008. His main research interest is the design and synthesis of bioactive lead compounds for anticancer, antiviral, and metabolic disease drug discovery. He has received a number of well recognized awards including "the State Council Special Allowance", the 6th "Wuxi AppTec Bioorganic Chemistry Award", the 10th "Dingying Science and Technology Award" of Guangdong Province, "100 Talent Program Award" of Chinese Academy of Sciences, and "Scientific Excellence Award" of Guangzhou City, etc. He has co-authored over 30 international patents and about 80 publications in Angew Chem. Int. Ed., J. Am. Chem. Soc. and J. Med. Chem., etc. He also serves as an editorial board member for the international journals such as J. Med. Chem., ACS Med. Chem. Lett and Chin. J. Pharm. Sci. (English).

Notes:

Jack Flanagan, Ph.D.

Title & Affiliation:

Senior Research Fellow, Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland

E-mail address: j.flanagan@auckland.ac.nz

Telephone: 64-9-373-7599x86155

Biography:

Dr. Flanagan obtained his B.S. (Honors) in Biochemistry and Molecular Genetics at Victoria University of Wellington, New Zealand, and went on to doctoral studies at the John Curtin School of Medical Research, the Australian National University, Australia investigating structure function relationships of glutathione transferases using molecular modelling and biochemical methods. This was followed by postdoctoral research at the Biomedical Research Centre, University of Dundee, United Kingdom investigating cytochromes P450 ligand interactions, followed by prostaglandin D2 synthase inhibitor discovery as a Howard Florey Centenary Fellow at the Institute for Molecular Bioscience. Dr. Flanagan is currently a Senior Research Fellow at the Auckland Cancer Society Research Centre and an Associate Investigator of the Maurice Wilkins Centre for Biodiscovery at The University of Auckland, New Zealand, where he uses structure based methods for inhibitor discovery and design, and develops tools to investigate cell signaling pathways.

Notes:

Zhaobing Gao, M.D., Ph.D.

Title & Affiliation:

Professor of Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China

E-mail address: zbgao@simm.ac.cn

Telephone: 86-21-20239067 Fax: 86-21-20239067

Biography:

Dr. Zhaobing Gao received his Ph.D. degree in pharmacology from Chinese Academy of Science in 2006. Thereafter, he worked at Johns Hopkins University as a postdoctoral fellow. He returned to Shanghai Institute of Materia Medica, Chinese Academy of Sciences and was appointed to the faculty in 2010. His research mainly focuses on the discovery of modulators of ion channels by electrophysiology and high-throughput screening. He is also interested in the application of bi-layers lipid membrane (BLM) system in pharmacological studies.

Notes:

Brigitte Gicquel, Ph.D.

Title & Affiliation:

Head of the Mycobacterial Genetics Unit
Director of the "Tuberculosis" Pasteur Course
Institut Pasteur, Paris, France
Visiting Porfessor at the Institut Pasteur of Shanghai

E-mail address: brigitte.gicquel@pasteur.fr

Telephone: 33-144389153 Fax: 33-145688843

Biography:

Prof. Brigitte Gicquel, Head of the Mycobacterial Genetics Unit at the Institut Pasteur, has developed the first genetic approach to investigate tuberculosis (TB) infection at a molecular level. She has been working as a visiting professor at the Institut Pasteur of Shanghai since 2012. Her team has developed the first PCR test for TB diagnosis and probes for genotyping (IS6110). She developed mycobacterial genetic tools, shuttle vectors, transposons, systems for gene inactivation and studied host-pathogen interactions at the level of the pathogen and of the host. She also discovered virulence factors of the pathogen and identified the major receptor of M. tuberculosis on dendritic cells (DC-SIGN). Her group has recently identified horizontal genetic transfer and important polymorphisms in M. tuberculosis' DNA repair genes. Prof. Brigitte Gicquel is coordinating the E.C. project Nanotherapeutics for Antibiotic Resistant Emerging Bacterial Pathogens (NAREB). She has organized international training workshops in Shanghai with the Fudan University and the Shanghai CDC (2008 and 2012, respectively). She was a member of the IMMYC committee at WHO, the Basic Immunology and Infectious Diseases Panel at the Wellcome Trust and several national committees. She is a member of EMBO.

Notes:

Chun Guo, Ph.D.

Title & Affiliation:

Professor of Medicinal Chemistry, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, China

E-mail address: gc_66888@163.com

Telephone: 86-24-23986425

Biography:

Professor Guo obtained his bachelor's degree in medicinal chemistry in 1985, master's degree in 1993, and a doctorate degree in 2002 from Shenyang Pharmaceutical University. From September, 1999 to September, 2001 he worked at School of Pharmacy, University of California, San Francisco, USA, as a visiting scholar. From 1985 to 1988, he served as an engineer at Northeast Pharmaceutical Group Co., Ltd. (NEPG). He has been teaching at Shenyang Pharmaceutical University since 1999. Professor Guo's research interests include R&D of antifungal and anti-parasitic drugs.

Notes:

De-An Guo, Ph.D.

Title & Affiliation:

Professor of Pharmacognosy, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China

E-mail address: daguo@simm.ac.cn

Telephone: 86-21-50271516 Fax: 86-21-50272789

Biography:

De-An Guo serves as Director of the State Engineering Laboratory for Traditional Chinese Medicine (TCM) Standardization Technology and Director of the Shanghai Research Center for TCM Modernization at Shanghai Institute of Materia Medica, Chinese Academy of Sciences. His research has centered on TCM analysis, quality and metabolisms. He earned his doctorate degree in Pharmacognosy from Beijing Medical University in 1990, and pursued his postdoctoral studies in Texas Tech University thereafter. His many accomplishments include more than 480 published scientific papers to date, among which 310 papers were in SCI cited journals with over 4000 citations. Dr. Guo acted as the editor-in-chief of the 2010 English edition of Chinese Pharmacopoeia. At present, he is Associate Editor, Editor or Editorial Board Member of 16 highly respected international scientific journals, including Journal of Ethnopharmacology, Planta Medica and Phytomedicine. Dr. Guo is an expert committee member of the United States Pharmacopeia and a member of the American Botanical Council Advisory Board.

Notes:

Yue-Wei Guo, Ph.D.

Title & Affiliation:

Professor of Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China

E-mail address: ywguo@simm.ac.cn

Telephone: 86-21-50805813 Fax: 86-21-50805813

Biography:

Yue-Wei Guo has completed his Ph.D. from Naples University and postdoctoral studies from both Istituto di Chimica Biomoleculare-CNR, Italy and Hokkaido University, Japan. In year 2000, he moved, as a Professor of Chemistry, to Shanghai Institute of Material Medica, Chinese Academy of Sciences. In these years his main research interests have been in the field of natural product chemistry of marine organisms, such as algae, mangrove, porifera, gorgonians and molluscs, particularly focused on the structural elucidation of chemical mediators and biological studies. His more recent interests are directed to the chemical ecology of unprotected marine molluscs from South China Sea and Chinese mangrove plants. He has published more than 290 papers in reputed journals and served as editorial board members of several respected national/international journals. He has won several academic prizes, including 2010 "Paul Scheuer Marine Biotechnology Prize".

Notes:

Deborah Hay, Ph.D.

Title & Affiliation:

Associate Professor, School of Biological Sciences, The University of Auckland, New Zealand

E-mail address: dl.hay@auckland.ac.nz

Biography:

Debbie Hay is Associate Professor at the School of Biological Sciences (University of Auckland) with industry experience (Glaxo Wellcome). Debbie obtained her Ph.D. in Molecular Pharmacology from Imperial College, London in 2002 and then moved to Auckland. Debbie is a Principal Investigator of the Centre for Brain Research and Associate Investigator of the Maurice Wilkins Centre. Debbie is investigating new approaches to treating several diseases, including migraine (CGRP), cancer (adrenomedullin), lymphatic insufficiency (adrenomedullin) and obesity (amylin). The core focus of her research is G protein-coupled receptors for peptide hormones. She has more than 90 publications in this area.

Notes:

Ti He, Ph.D.

Title & Affiliation:

Manager, International Cooperation. ADICON Clinical Laboratory Inc., Shanghai, China

E-mail address: ti.he@adicon.com.cn

Telephone: 86-21-34978009 Fax: 86-21-34978009

Biography:

Dr. Ti He was graduated from Fudan University with a bachelor degree and University of Alabama at Birmingham with a Ph.D. degree. His doctoral training, mentored by Dr. Max Cooper, the pioneer of B cells, focused on molecular mechanisms of immune system abnormalities and defects. He has published several peer-reviewed papers and co-discovered one novel diagnostic marker in CLL. Experienced in molecular biology, particularly in molecular pathology, his responsibilities in ADICON include setting-up molecular pathology capacities. He involves in several multi-center clinical study projects in oncology and hematology, including innovative drug clinical trials, biomarker screening and validation.

Notes:

Daniel Hoyer, Ph.D.

Title & Affiliation:

Daniel Hoyer, Ph.D., D.Sc., FBPharmacolS
Chair and Head, Department of Pharmacology and Therapeutics, Melbourne Medical School, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Australia
Honorary Professorial Fellow, The Florey, Australia

E-mail address: d.hoyer@unimelb.edu.au

Telephone: 61-3-9035 9518

Biography:

Daniel Hoyer got his Ph.D. and D.Sc. in Pharmacology from Universite Louis Pasteur, Strasbourg, France. Following a postdoctoral training at University of Pennsylvania Medical School, Hoyer joined Sandoz in Basel. He has over 25 years of drug discovery and development experience in pharma and academia (Sandoz: 1983-1997; Novartis: 1997-2012; Scripps: 2004-present), and mangaged pharmacology research groups, drug discovery programs and translational biology. He was responsible for extensive cross disciplinary internal and external collaborations and held leadership positions of many learned societies and numerous editorial boards (1998: Novartis Leading Scientist; 2002: Highly Cited Researcher, ISI, Pharmacology; 2003: Manfred Zimmermann Award; 2003: Top Ten in Pharmacology, ISI; 2004: Fellow of the British Pharmacological Society).

Notes:

Wei Hu, Ph.D.

Title & Affiliation:

Professor, Department of Microbiology and Microbial Engineering,
School of Life Sciences, Fudan University, China
Adjunct Professor at National Institute of Parasitic Diseases,
Chinese Center for Diseases Control and Prevention, China

E-mail address: huw@fudan.edu.cn

Telephone: 86-21-65643031 Fax: 86-21-54653512

Biography:

Wei Hu is a Professor at School of Life Sciences, Fudan University. She obtained her master's degree from Central China Normal University in 1996 and her Ph.D. from Chinese Center for Disease Control and Prevention in 2002. She worked for the National Institute of Parasitic Diseases, China Center for Disease Control and Prevention from 1996 to 2012. She was the Chief of Key Laboratory of Parasitology and Vector Biology, National Institute of Parasitic Diseases, and Coordinator of Diagnostic Group of the Chinese Network for Drugs and Diagnostics Innovation. In 2010, she was invited to attend the Helminth Drug Initiative Committee meeting held in Geneva. She has focused on the transcriptome, proteome and genome investigation in the past 10 years and is now looking for new targets for diagnosis and drug development based on the genomics data.

Notes:

Palle Høy Jakobsen, Ph.D.

Title & Affiliation:

Palle Høy Jakobsen, D.MSc., Ph.D.
Director and Head, R&D Academic Relations, Novo Nordisk A/S, Denmark

E-mail address: phja@novonordisk.com

Telephone: 45-44426287

Biography:

Palle Høy Jakobsen is Director and Head of R&D Academic Relations in Novo Nordisk A/S. He has a master degree and a Ph.D. from the Faculty of Science, University of Copenhagen and a doctorate degree from the Faculty of Medical Science, University of Copenhagen, respectively. He has received executive training at INSEAD, Stanford and Harvard Business School. He conducted research previously mainly about malaria and immunology and is author/coauthor of more than 50 publications. He acted as an expert reviewer for the European Commission in relation to grant applications for research and development collaborations between Europe and the third world developing countries in 1995-1997. He established and became a coordinator of The African Malaria Vaccine Testing Network (1995–1997), supported by the UNDP/World Bank/World Health Organization and the European Commission. He joined Novo Nordisk the first time in 1997 doing patent strategies and negotiating licensing deals. He left Novo Nordisk in 2001 in order to do consulting work for biotech. In 2005 he joined Novo Nordisk again and became a senior licensing director in business development. In 2012 he became Head of R&D Academic Relations. In this role he has entered collaboration agreements with Oxford University, Stanford University and a number of other universities. He runs both postdoctoral and Ph.D. fellowship programs supporting more than 90 young researchers.

Notes:

Henry Ji, Ph.D.

Title & Affiliation:

President and CEO, Sorrento Therapeutics, Inc., USA

E-mail address: hji@sorrentotherapeutics.com

Telephone: 858-210-3701 Fax: 858-210-3759

Biography:

Dr. Ji received his B.S. from Fudan University in 1985, his Ph.D. degree from University of Minnesota in 1993 and postdoctoral training in Human Genome Sciences from 1993-1995. Dr. Ji founded Stratagene Genomics in 1997 and served as President and CEO from 1997 to 1999. He was Director of Business Development for Stratagene Corporation from 1999 to 2001 and promoted to Vice President of Business Development of Stratagene in 2001. Dr. Ji was Vice President of Business Development of CombiMatrix from 2001 to 2002. He is a co-founder of Sorrento Therapeutics, served as its Chief Scientific Officer from 2008 to 2012. He was the interim CEO of Sorrento Therapeutics from 2011 to 2012 and its President and CEO from 2012 to present. Dr. Ji successfully listed Sorrento Therapeutics (SRNE) on the NASDAQ National Market in 2013 with a current market capitalization of more than $200 million.

Notes:

Hualiang Jiang, Ph.D.

Title & Affiliation:

Director and Professor of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China

E-mail address: hljiang@simm.ac.cn

Telephone: 86-21-50805873 Fax: 86-21-50805873

Biography:

Dr. Hualiang Jiang obtained his bachelor's degree from the Department of Chemistry, Nanjing University in 1987. In September 1989, he entered East China Normal University and received his master degree in physical chemistry (quantum chemistry) in 1992. From September 1992 to July 1995, he studied in Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences for his Ph.D. degree and received his degree in organic chemistry in 1995. He is currently a professor of SIMM. He also assumes the directorship of the institute in March, 2014. He is the chief scientist of a 973 project and holds memberships at the scientific committee of several major research programs in China, such as 863 Program in Biology and Medical Technology, National Basic Research Program in Protein Science, and Major Research Project of the National Natural Science Foundation. He also serves on editorial boards for several journals such as Journal of Medicinal Chemistry (Senior Editor) and ChemMedChem. His numerous awards include Natural Sciences Award of China, 5th Prize of Young Scientist Awards of China, Natural Science Award of Shanghai, and Top10 Outstanding Scientists of Shanghai (2001-2003).

Notes:

Jian-Dong Jiang, M.D., Ph.D.

Title & Affiliation:

Director, Institute of Materia Medica, Chinese Academy of Medical Sciences/Peking Union Medical College, China

E-mail address: jiang.jdong@163.com

Biography:

Jian-Dong Jiang received his M.D. degree from Shanghai Medical College of Fudan University. He then spent 18 years in the Department of Internal Medicine at the Mount Sinai Hospital in New York. Dr. Jiang came back to China in 1999 and worked as an institute director in Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences (CAMS)/Peking Union Medical College (PUMC) in Beijing. His research field on drug R&D covers infectious diseases, cancer and metabolic disorders. Dr. Jiang has published over 130 research articles in journals like Nature Medicine, Cancer Cell, Hepatology, PNAS, et al. Two accomplishments have been translated into clinical use serving patients: one for drug-resistant hepatitis B and the other for lowering blood lipids. Dr. Jiang is currently the President of the Institutes of Pharmaceutical Sciences as well as Director of Institute of Materia Medica, CAMS/PUMC. He also serves as Editor-in-Chief of Acta Pharmaceutica Sinica.

Notes:

Rasmus Jorgensen, Ph.D.

Title & Affiliation:

Vice President of Diabetes Research China, Novo Nordisk Research Centre, China

E-mail address: rsjr@novonordisk.com

Telephone: 86-10-53211132

Biography:

Rasmus Jorgensen, Ph.D., is Vice President of Novo Nordisk Diabetes Research China. Novo Nordisk is a global healthcare company with 90 years of innovation in diabetes care. Dr. Jorgensen obtained his Ph.D. from the University of Copenhagen in the area of GPCR signaling. Afterwards, Dr. Jorgensen worked for the biotech company 7TM Pharma focusing on drug discovery projects targeting GPCRs in the metabolic disease area. For the past six years, Dr. Jorgensen has been working for Novo Nordisk in diabetes research and the last two years he has been heading the Novo Nordisk Diabetes Research Centre in Beijing, China. Dr. Jorgensen is trained in cell biology and has been working on drug discovery in the obesity and diabetes area for more than 10 years. With experience in drug discovery project management and line management for different expertise areas such as in vivo pharmacology, in vitro biology and protein engineering, Dr. Jorgensen has broad expertise and experience in diabetes and obesity drug discovery.

Notes:

Yuehai Ke, Ph.D.

Title & Affiliation:

Associate Dean, School of Basic Medical Sciences, Zhejiang University, China

Executive Director, Research Center for Molecular Medicine, Zhejiang University, China

Professor of Pathology, Zhejiang University School of Medicine, China

E-mail address: yke@zju.edu.cn

Telephone: 86-571-88208713 Fax: 86-571-88208583

Biography:

Dr. Ke studied biochemistry at Zhejiang University, and continued his master degree in medical science at the Chinese Center for Disease Control and Prevention (CDC) in 1995. He earned his Ph.D. degree from Fudan University in 2001, and received his postdoctoral training at laboratory of G.S. Feng from Sanford-Burnham Medical Research Institute (2002-2007), and was recruited to School of Medicine, Zhejiang University in early 2008.

Notes:

Sunghoon Kim, Ph.D.

Title & Affiliation:

Director, Medicinal Bioconvergence Research Center

Professor, Department of Molecular Medicine and Biopharmaceutical Sciences World Class University Program,

Seoul National University, Korea

E-mail address: sungkim@snu.ac.kr

Telephone: 82-2-880-8180 Fax: 82-2-875-2621

Biography:

Sunghoon Kim received bachelor's degree at Seoul National University College of Pharmacy, master's degree at Korea Advanced Institute of Science and Technology Department of Biological Sciences and Ph.D. degree at Division of Biology and Medicine, Brown University, USA. He then worked as postdoctoral fellow at MIT. He is currently a professor at College of Pharmacy and also at Graduate School of Convergence Technology of Seoul National University. He received several prestigious awards provided by various scientific communities as well as by Korean government such as the Korea Scientist Award (2003), the Scientist of the Year (2006) and The Best Scientist Award (2012). Since 2010, he is leading "Medicinal Bioconvergence Research Center" that is one of the biggest top-down research projects launched by the Ministry of Science, ICT and Future Planning (MSIP). In this project, he is paving a rapid and efficient target identification and validation system through integrated biology with convergence technologies and is linking this system to facilitate novel drug discovery.

Notes:

Shihuan Kuang, Ph.D.

Title & Affiliation:

Associate Professor, Department of Animal Science, Purdue University, USA
Faculty Member, Center for Cancer Research, Purdue University
Faculty Member, Center for Drug Discovery, Purdue University
Visiting Professor, Chinese Academy of Medical Sciences, China

E-mail address: skuang@purdue.edu

Telephone: 765-494-8283 Fax: 765-494-6816

Biography:

Dr. Shihuan Kuang received his Ph.D. from University of Alberta in 2002 and was then trained as a postdoctoral fellow at Washington University School of Medicine and Ottawa Hospital Research Institute. He became a faculty of Animal Sciences, Purdue University in 2008 and was promoted to tenured associate professor in 2013. Dr. Kuang is currently a faculty member of Purdue University Center for Drug Discovery and Center for Cancer Research. He is also a visiting professor of Chinese Academy of Medical Sciences. Dr. Kuang's basic research in adult stem cells and muscle-fat interaction translates to applications in both muscle health (muscular dystrophy) and metabolic syndromes. Dr. Kuang has published over 60 refereed journal papers and book chapters, served on the editorial boards or as a referee for many journals and grant panels. His research has been supported by National Institutes of Health, American Cancer Society, Muscular Dystrophy Association and United States Department of Agriculture.

Notes:

Ho Jeong Kwon, Ph.D.

Title & Affiliation:

Professor, Chair, Department of Biotechnology and Director, Chemical Genomics National Research Laboratory, Yonsei University, Korea

E-mail address: kwonhj@yonsei.ac.kr

Telephone: 82-2-2123-5883 Fax: 82-2- 362-7265

Biography:

Prof. Dr. Ho Jeong Kwon got his B.Sc. from Seoul National University, Korea and completed his M.S. and Ph.D. from University of Tokyo, Japan and postdoctoral studies at Harvard University, USA. He is currently Professor at Department of Biotechnology, Yonsei University, Korea and Director of Chemical Genomics National Research Laboratory. He served as a science advisory member of Institute of Pasteur Korea, a council member of HUPO, the president of KHUPO and a council member, secretary general and vice president of AOHUPO. He has published more than 130 papers in reputed journals including Nature Medicine, Nature Chemical Biology, PNAS, Chemistry and Biology, JBC, J. Proteomics Research and served as editorial board members of repute journals such as J. Proteomics, Int. J. Proteomics, J. of Proteomics and Bioinformatics, J. Antibiotics, Oncology Research, J. Chemical Biology, J. Integrative Omics, J. Microbiology and Biotechnology and BMB reports.

Notes:

Jesper Lau, Ph.D.

Title & Affiliation:

Vice President, Diabetes Protein and Peptide Chemistry, Diabetes Research Unit, Novo Nordisk A/S, Denmark

E-mail address: jela@novonordisk.com

Telephone: 45-3075-4872

Biography:

Dr. Jesper Lau studied biology and chemistry at University of Southern Denmark. After his Ph.D. in organic chemistry in 1990 and a research visitor stay in the group of Professor Barry Trost at Standford University in California, he joined Health Care Discovery at Novo Nordisk. In 1995 he became responsible for defining and implementing Combinatorial Chemistry in discovery projects at Novo Nordisk. In 2002 Jesper Lau was asked to establish a new department with focus on establishing technologies to improve the therapeutic properties of endogenous peptides and proteins. Dr. Jesper Lau has 20 years experience in pharmaceutical discovery and holds a broad experience in small molecule based therapeutics as well as a comprehensive experience in protein engineering and has collaborated with several international research teams in various countries. He has optimised numerous leads to clinical candidates within diseases in the central nervous system, growth hormone disorders and especially within diabetes care with particular interest in glucagon-like peptide-1 (GLP-1) where he was project leader responsible for once weekly GLP-1 and is first inventor of semaglutide. In 2008 he was appointed Vice President of Protein and Peptide Chemistry with a staff of about 50 researchers.

Notes:

Jia Li, Ph.D.

Title & Affiliation:

Deputy Director and Professor of Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China
Head of Assay Development Department, the National Center for Drug Screening, China

E-mail address: jli@mail.shcnc.ac.cn

Telephone: 86-21-50801552 Fax: 86-21-50800721

Biography:

Jia Li obtained his bachalor's degree in Pharmacy from Zhejiang Medical University in 1992, and his Ph.D. degree in Pharmacology from Shanghai Institute of Materia Medica, Chinese Academy of Sciences in 2000. Then he worked for the National Center for Drug Screening as the head of Assay Development Department. Dr. Li was appointed as a principle investigator at Shanghai Institute of Materia Medica, Chinese Academy of Sciences in 2002 and full professor in 2007. In 2010, he was appointed as Assistant Director of Shanghai Institute of Materia Medica, Chinese Academy of Sciences and promoted to Deputy Director in 2014. He also serves as Adjunct Professor at East China Normal University and ShanghaiTech University.

Notes:

Jingya Li, Ph.D.

Title & Affiliation:

Professor of Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China

E-mail address: jyli@simm.ac.cn

Telephone: 86-21-50801313 Fax: 86-21-50800721

Biography:

Dr. Jingya Li obtained her Ph.D. degree in Pharmacology from Shanghai Institute of Materia Medica, Chinese Academy of Sciences in 2003. Then she began her research career in the National Center for Drug Screening, focusing on the drug discovery for metabolic diseases. As a scholar, Dr. Li visited Garvan Institute of Medical Research in 2005, and participated in the joint Sino-Australia research project.

Notes:

Xuejun Li, Ph.D.

Title & Affiliation:

Department of Pharmacology, School of Basic Medical Sciences, Peking University, China

E-mail address: xjli@bjmu.edu.cn

Telephone: 86-10-82802863 Fax: 86-10-82802863

Biography:

Professor Xuejun Li currently is Professor of Pharmacology, School of Basic Medical Sciences, Peking University. She graduated from the Faculty of Medicine, Peking University and then worked in the Department of Pharmacology. Between 1992 and 1994, she studied in the Rockefeller University, USA as a postdoctoral fellow. In June, 1996, she was promoted to Professor at Peking University. From 2003 to 2008, she worked as Associate Dean of School of Basic Medical Sciences, and for more than 10 years, she chaired the Department Pharmacology. Presently, she serves as Vice President of Chinese Pharmacological Society. Her current research interest focuses on molecular pharmacology and drug discovery. Up to date she has published more than 200 scientific articles and obtained more than 10 research grants from the Chinese government.

Notes:

Yang Li, Ph.D.

Title & Affiliation:

Professor of Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China

E-mail address: liyang@simm.ac.cn

Telephone: 86-21-50803107 Fax: 86-21-50803107

Biography:

Dr. Yang Li received his B.S. from Shandong University and got his master degree from East China Normal University. After receiving his Ph.D. from Shanghai Institute of Materia Medica, Chinese Academy of Sciences in 2002, he worked as postdoctoral researcher and assistant instructor at the University of Texas Health Science Center at San Antonio and Southwestern Medical Center at Dallas from 2002 to 2009. From September 2009, he became a principal investigator at Shanghai Institute of Materia Medica, Chinese Academy of Sciences through "Hundred Talents" program. Dr. Yang Li studies the physiology and pharmacology of potassium channels and dopamine receptors by combining the methods of single channel electrophysiology and crystallography. The mission of Li's laboratory is to explore therapentic effects on neuronal diseases, such as major depression, anxiety, and schizophrenia, by pharmacological probes from natural products.

Notes:

Jiayu Liao, Ph.D.

Title & Affiliation:

Associate Professor of Bioengineering, Bourns College of Engineering, Biomedical Program, Stem Cell Center, and Institute for Integrative Genome Biology, University of California at Riverside, USA

E-mail address: jiayu.liao@ucr.edu

Telephone: 951-827-6240 Fax: 951-827-5696

Biography:

After Dr. Liao obtained his B.S. in Biochemistry and worked at National Protein Engineering Laboratory at Peking University, he obtained his Ph.D. in Biological Chemistry from University of California at Los Angeles in 1999. Before he joined the the Genomic Institute of Novartis Research Foundation (GNF) as founding scientist of GPCR platform, he conducted his postdoctoral training in Peter G. Schultz's laboratory at The Scripps Research Institute and GNF. Dr. Liao joined the University of California at Riverside in 2006 as a founding faculty member of the Department of Bioengineering and Bioengineering Interdepartmental Graduate Programs. He is founder and Chairman for two biotechnology companies, Argusina and Attaisina, a spin-off company from University of California. He serves several prestigious panels in NIH, University of California, and Chinese Natural Science Foundation. He also serves as Adjunct Professor at the National Center for Drug Screening. He has filed more than 20 patents covering various disciplines from drug discovery to technologies, and his papers has been cited more than 2300 times.

Notes:

Gang Liu, EMBA

Title & Affiliation:

Vice President and Secretary General, Shanghai Pudong Bio Industry Association
Assistant General Manager, Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co., Ltd., China

E-mail address: liug@zjbpb.com

Telephone: 86-21-50801766 Fax: 86-21-58550967

Biography:

Mr. Liu is currently the Vice President and Secretary General of Shanghai Pudong Bio Industry Association (SPBIA), and Assistant General Manager of Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co., Ltd. (ZJBPB). This State Biotech and Pharmaceutical Industrial Cluster focuses on the centralization and development of innovative enterprises in the field of biotechnology and pharmaceutical industries, and is known as "Zhangjiang Pharmaceutical Valley". He has been in charge of pharmaceutical industry research and drug IP customers services at Zhangjiang since 2005. Mr. Liu obtained his EMBA from Fudan University.

Notes:

Hong Liu, Ph.D.

Title & Affiliation:

Professor of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China

E-mail address: hliu@simm.ac.cn

Telephone: 86-21-50807042 Fax: 86-21-50807042

Biography:

Prof. Hong Liu received her M.S. and Ph.D. in medicinal chemistry from China Pharmaceutical University in 1996 and 1999, respectively. After postdoctoral training at Shanghai Institute of Materia Medica, Chinese Academy of Sciences, she was appointed to the faculty there in 2001. As a visiting scientist, she worked at University of Texas Medical Branch at Galveston for two years. Dr. Liu's efforts mainly dedicate to the research of pharmaceutical chemistry and drug design and discovery. She is also focusing on the development of new organic synthetic methodologies, building focused combinatorial libraries, and the discovery and optimization of lead compounds for new drugs.

Notes:

Fiona Marshall, Ph.D.

Title & Affiliation:

Chief Scientific Officer
Heptares Therapeutics Ltd.
Hertfordshire, UK

E-mail address: fiona.marshall@heptares.com

Telephone: 44-1707-358638 Fax: 44-1707-358640

Biography:

Fiona Marshall is Chief Scientific officer of Heptares Therapeutics. She has a B.Sc. in Biochemistry from Bath University and a Ph.D. in Neuroscience from Cambridge. She has 25 years' experience in drug discovery. She spent 12 years at GlaxoSmithKline where she held a number of senior positions including Head of the Department of Molecular Pharmacology. Whilst at GSK her team was responsible for the identification that the GABAB receptor functioned as a heterodimer, the identification of RAMP accessory proteins and the deorphanning of the nicotinic acid receptor and the free fatty acid receptors. She was Director of Discovery Pharmacology, Europe for Millennium Pharmaceuticals and then spent several years as an independent consultant to a variety of venture capital and biotech companies. In 2007 she co-founded Heptares, a drug discovery and development company, based in the UK, which specializes in structure based design applied to GPCRs. Heptares have solved the structure of many GPCRs, using its StaR® technology and used these to enable drug discovery projects across a wide variety of targets both for internal discovery and in partnership. Heptares purified GPCRs are also effective as antigens for antibody discovery. Heptares has collaborations with AstraZeneca, Takeda, MedImmune, Cubist and Morphosys.

Notes:

Solomon Nwaka, Ph.D.

Title & Affiliation:

Acting Director, the African Network for Drugs and Diagnostics Innovation (ANDI), Ethiopia
Leader, Drug Discovery for Infectious Tropical Diseases and Innovation for Product Development in Developing Countries, Special Programme for Research and Training in Tropic Diseases

E-mail address: nwakas@who.int

Telephone: 41-22-791-3767 Fax: 41-22-791-4854

Biography:

Dr. Solomon Nwaka's scientific and management career spans different public and international organizations, biopharmaceutical industry and public-private partnerships in several countries including the USA, Canada, Germany, Japan, Belgium, Italy, Switzerland and Nigeria. Presently, he is the Acting Director of the African Network for Drugs and Diagnostics Innovation (ANDI) and the Leader of Drug Discovery for Infectious Tropical Diseases and Innovation for Product Development in Developing Countries at the Special Programme for Research and Training in Tropical Diseases, World Health Organization, Geneva, Switzerland.Prior to joining WHO, he was the Director of Drug Discovery at the Medicines for Malaria Venture (MMV), a public-private partnership. He also worked as a Senior Scientist and member of the management team at a Canadian biopharmaceutical company. He has published broadly on drug R&D, public-private partnerships, as well as innovative models to stimulate health product R&D and access in developing countries. He holds a Ph.D. with emphasis on molecular biology.

Notes:

Re
NWAKA, Solomon 3/7/2014 10:24 PM
To: Ming-Wei Wang; Ming-Wei Wang;

Dear Ming Wei,

I am very sorry to inform you that I would have to cancel my trip to Shanghai this month due to other urgent matters. I was really looking forward to this....my apologies.

Solomon.

Sent from my iPad

Hiroki Oguri, Ph.D.

Title & Affiliation:

Associate Professor, Division of Chemistry, Graduate School of Science, Hokkaido University, Japan

E-mail address: oguri@sci.hokudai.ac.jp

Telephone: 81-11-706-3429 Fax: 81-11-706-3448

Biography:

Hiroki Oguri received B.S. (1993) and Ph.D. (1998) degrees from Tohoku University under the supervision of Profs. Masahiro Hirama and Tohru Oishi, and was then appointed as an assistant professor in the research group of Prof. M. Hirama (1998–2003). Then, he worked with Prof. Stuart L. Schreiber at the Department of Chemistry and Chemical Biology, Harvard University for one year as a visiting scientist. In 2004, he joined the Division of Chemistry, Graduate School of Science, Hokkaido University as an associate professor in the research group of Prof. Hideaki Oikawa. Dr. H. Oguri was honored with the Inoue Research Award for Young Scientists (2000), the Young Scientist's Research Award in Natural Product Chemistry (2001), the Chemical Society of Japan Award for Young Chemists (2005), and Banyu Chemist Award (2010). He has been concurrently appointed as an investigator at CRIS (2007-2010), Hokkaido University and a JST PRESTO researcher (2013-present).

Notes:

Junko Ohkanda, Ph.D.

Title & Affiliation:

Associate Professor, the Institute for Chemical Research, Kyoto University, Japan

E-mail address: johkanda@scl.kyoto-u.ac.jp

Telephone: 81-774-38-3222 Fax: 81-774-38-3226

Biography:

Junko Ohkanda earned a M.Sc. from Ochanomizu University, and received her Ph.D. from The University of Tokyo in 1990 and 1996, respectively. After working at Richo Corp. and Seikei University, she joined the Professor Andrew Hamitlon's research group at Yale University in 1998 as a Postdoctoral Research Scientist. She served Achillion Pharmaceuticals, Inc. (Connecticut, US) before she returned to Japan in 2004. She was first appointed as a Lecturer at Tokyo Gakugei University, and was later promoted to an Associate Professor at Osaka University in 2005. In April 2013, she relocated to the Institute for Chemical Research, Kyoto University and joined Professor Motonari Uesugi's group as an Associate Professor. Her research interests include bioorganic medicinal chemistry as well as chemical biology, in which she focuses on structure-based design of mid-sized synthetic agents using peptides and natural products for disrupting and detecting protein-protein interactions.

Notes:

Weiqing Pan, Ph.D.

Title & Affiliation:

Director, Department of Tropical Infectious Diseases, The Second Military Medical University, China

Director, World Health Organization Collaborative Center for Gene Synthesis and Expression, China

Director, Institute for Infectious Diseases and Vaccine Development, Tongji University, China

E-mail address: wqpan0912@aliyun.com

Telephone: 86-21-81871010 Fax: 86-21-65331272

Biography:

Prof. Pan obtained his Ph.D. degree in Molecular Biology at ZMBH of Heidelberg University, Germany in 2000. He is full Professor for Pathogen Biology since 2001 at The Second Military Medical University (SMMU). Currently, Prof. Pan is director of the Department of Tropical Infectious Diseases at SMMU, Director of World Health Organization Collaborative Center for Gene Synthesis and Expression and Director of Institute for Infectious Diseases and Vaccine Development of Tongji University in Shanghai. Prof. Pan is vice-chairman of Chinese Society for Tropical Medcine and Parasitology and vice-chairman of Shanghai Society for Parasitology. His scientific interests include recombinant vaccine R&D, molecular biology of human parasites including malaria parasite and schistosoma involving transcription regulation, drug resistance, etc. He constructed the PfCP-2.9 malaria vaccine that was supported by WHO and the Bill and Melinda Gates Foundation. He has received numerous scientific awards including National Outstanding Youth Fund and as a chief scientist of the National "973" project.

Notes:

Seung Bum Park, Ph.D.

Title & Affiliation:

Professor and Vice Chair, Chemistry Department, Seoul National University, Korea

E-mail address: sbpark@snu.ac.kr

Telephone: 82-2-8809090 Fax: 82-2-8844025

Biography:

Seung Bum Park received his B.S. (1993) in chemistry and M.S. (1997) in organic chemistry from Department of Chemistry, Yonsei University, Korea. After one and a half years of military service in Korean Air Force, he started his graduate study at Texas A&M University and received a Ph.D. in 2001 under the supervision of Prof. Robert F. Standaert. Then, he was appointed as a HHMI Postdoctoral Research Fellow in the Department of Chemistry and Chemical Biology at Harvard University (with Prof. Stuart L. Schreiber). In 2004, he started his independent carrier as an Assistant Professor, and promoted to an Associate Professor with tenure (2008) in Chemistry Department at Seoul National University. He finally promoted to a full professor (2013) and currently serves as a vice chair of Chemistry Department. In 2009, he spent his sabbatical as a visiting professor at the Scripps Research Institute, San Diego, USA (with Prof. Peter Schultz). Since April 2012, he has been serving as an associate editor of Molecular BioSystems (Royal Society of Chemistry), and as editorial advisory board member of several peer-reviewed journals. He was appointed as a fellow of Royal Society of Chemistry (FRSC in 2013) and has published about 110 scientific papers, 3 book chapters and filed 25 patents as of December 2013.

Notes:

Rosanna Peeling, Ph.D.

Title & Affiliation:

Professor and Chair of Diagnostics Research
Director, International Diagnostics Centre, London School of Hygiene and Tropical Medicine, UK

E-mail address: rosanna.peeling@lshtm.ac.uk

Telephone: 44-207-927-2529

Biography:

Dr. Peeling is Professor and Chair of Diagnostics Research at the London School of Hygiene and Tropical Medicine (LSHTM) and the Director of the International Diagnostics Centre (IDC). Trained as a medical microbiologist, Dr. Peeling was the Research Coordinator and Head of Diagnostics Research at the UNICEF/UNDP/World Bank/WHO Special Programme on Research and Training in Tropical Diseases (WHO/TDR) in Geneva, Switzerland, and the co-director of the National Laboratory for Sexually Transmitted Diseases in Canada before assuming her current positions. Her work in WHO/TDR focused on setting international standards for diagnostic evaluations to inform policy and procurement. Dr. Peeling established the IDC at LSHTM to provide a global hub for advocating the value of diagnostics, fostering innovative research, and accelerating access to quality-assured diagnostics for global health. She has a strong interest in ethical issues associated with research in developing countries and was appointed the Chair of the WHO Research Ethics Review Committee (2004-2006). She was the recipient of a YM-YWCA Women of Distinction Award, a 5NR Award for Canadian Leaders of Sustainable Development. Her research was featured in a Discovery Channel documentary on Chlamydia and Infertility, and in Fighting Syphilis, in the highly acclaimed BBC Kill or Cure series.

Notes:

Adam Podmore, B.A.

Title & Affiliation:

Commercialization Manager, Biotechnology and Pharmaceuticals, UniServices, The University of Auckland, New Zealand

E-mail address: a.podmore@auckland.ac.nz

Telephone: 64-9-373-7599

Biography:

Over the last seven years at UniServices, Adam has commercialized technology through dozens of local and international licensing deals and raised several millions of dollars for start-up companies from The University of Auckland. Adam manages the UniServices Investment Committee for Biotechnology, Life Sciences and Pharmaceuticals. Before joining UniServices, Adam worked for several years for Trade New Zealand, Investment New Zealand and New Zealand Trade and Enterprise (NZTE) which included attracting investment in New Zealand biotechnology sector and developing a global network in the industry. Adam has a bachelor's degree in commerce and management (Economics) from Lincoln University.

Notes:

Barry Potter, Ph.D.

Title & Affiliation:

Barry V.L. Potter, DPhil, DSc, FMedSci
Professor and Head of Medicinal Chemistry, Department of Pharmacy and Pharmacology, University of Bath, UK

E-mail address: b.v.l.potter@bath.ac.uk

Telephone: 44-1225-386639 Fax: 44-1225-386114

Biography:

Barry Potter studied Chemistry at Oxford University, completing a DPhil on the stereochemistry of enzyme-catalysed phosphoryl transfer and receiving a DSc in 1993. After postdoctoral work in Oxford and at the Max-Planck-Institute for Experimental Medicine in Germany, he became Lecturer at Leicester University UK, winning a Lister Institute Fellowship, then moved to the chair of Medicinal Chemistry at Bath. Research interests are in mechanistic enzymology, the chemistry of signal transduction and anticancer drug discovery. He has brought academically-discovered drugs to multiple clinical trials and co-founded the spin-out company Sterix, acquired by a major pharma. He has published over 500 papers and is inventor of 45 granted US patent families. He is on editorial boards including the Journal of Medicinal Chemistry, ChemMedChem, Molecular Cancer Therapeutics and BJ ChemBio and is Associate Editor of the Journal of Steroid Biochemistry and Molecular Biology. He was elected to the UK National Academy of Medical Sciences and the Academia Europaea and has won four Royal Society of Chemistry medals, the GlaxoSmithKline International Achievement Award and was "Investigator of the Year" at the 2012 European Life Science Awards. He is a Wellcome Trust Senior Investigator and Visiting Professor of Medicinal Chemistry at Oxford University.

Notes:

Ronald J. Quinn, Ph.D.



Title & Affiliation:

Ronald J. Quinn, Ph.D., AM, FTSE, FRACI
Director and Professor, Eskitis Institute for Drug Discovery, Griffith University, Australia

E-mail address: r.quinn@griffith.edu.au

Telephone: 61-7-3735-6006

Biography:

Prof. Quinn is the Foundation Director of the Eskitis Institute at Griffith University, and an author of over 200 publications and patents. His research concentrates on the use of natural products as tools to understand interactions in biological systems and to build concepts around molecular recognition. He developed a novel approach to fragment-based drug discovery based on natural products and the use of bioaffinity mass spectrometry. He also developed Nature Bank as a state-of-the-art resource containing over 45,000 sample of plants and marine products collected from mega-diverse areas of tropical Queensland, Tasmania, Papua New Guinea, Malaysia and China in accordance with the Convention on Biological Diversity. He was honored as a recipient of a Member of the Order of Australia (AM) for service to scientific research, in the field of chemistry as a leader in the development of therapeutic compounds from marine organisms and plant materials. He received the Queensland Museum Medal 2012 for discovery of many new life forms as a consequence of biodiscovery. He is a Fellow of the Australian Academy of Technological Sciences and Engineering (ATSE–elected 2003) and a Fellow of the Royal Australian Chemical Institute (RACI). He also is a recipient of McCullough Robertson LSQ Industry Excellence Award (2013), and Honorary Professor at College of Pharmacy, South-Central University for Nationalities, China (2012).

Notes:

Zihe Rao, Ph.D.

Title & Affiliation:

President, Biophysical Society of China
Former President, Nankai University, Professor of Molecular Biophysics, Tsinghua University and Nankai University, China
Academician, Chinese Academy of Sciences

E-mail address: raozh@nankai.edu.cn

Biography:

Zihe Rao, Former President of Nankai University, Professor of Molecular Biophysics, Tsinghua University and Nankai University, is a structural virologist, mainly engaged in the study of three-dimensional structures of significant proteins and viruses related to human infectious diseases or with important physiological functions, as well as in innovative drug discovery. He has published more than 290 peer-reviewed papers to date in international scientific journals. Zihe Rao was elected as an acdemician of Chinese Academy of Sciences in 2003, a member of the Third World Academy of Sciences in 2004 and a fellow of Hertford College, Oxford, in 2011. He was elected as the president-elect of IUPAB in 2011. From March 2003 to April 2007, he served as Director-General of Institute of Biophysics, Chinese Academy of Sciences, and Director of the National Laboratory of Biomacromolecules.

Notes:

Siddhartha Roy, Ph.D.

Title & Affiliation:

Director, CSIR-Indian Institute of Chemical Biology, Kolkata, India

E-mail address: sidroykolkata@gmail.com

Telephone: 91-33-2413-1157 Fax: 91-33-2473-5197

Biography:

Dr. Roy obtained his Ph.D. degree in Chemistry from University of Delaware, USA, followed by postdoctoral studies at Brandeis University and National Institutes of Health, Bethesda. Currently he serves as the Director, CSIR-Indian Institute of Chemical Biology, Kolkata. His important research achievements include creation of hydropathy plot of proteins to distinguish between protein interiors and exteriors; first complete assignment of a nucleic acid imino proton spectra; demonstration of DNA sequence dependent conformation of transcription factors and its importance in transcription regulation; development of a thermodynamic model of regulation of transcription initiation. He has coordinated a new CSIR initiative on Synthetic and Systems Biology. He was a Visiting Professor, Osaka University and a Visiting Scientist, National Institutes of Health, Bethesda. He was awarded SS Bhatnagar Prize (India's highest scientific prize) and is the Founder President of Chemical Biology Society, India. Dr. Roy is a fellow of Indian Academy of Sciences and served as the President of West Bengal Academy of Science and Technology (State Academy).

Notes:

Peter Shepherd, Ph.D.

Title & Affiliation:

Deputy Director, Maurice Wilkins Centre
Chair of Queenstown Molecular Biology Meetings Society
Chair of Biochemical Journal Editorial Board
Professor, The University of Auckland, New Zealand

E-mail address: peter.shepherd@auckland.ac.nz

Telephone: 64-923-9891

Biography:

Professor Peter Shepherd graduated from Massey University and following postdoctoral positions at Harvard and Cambridge he became a staff member at University College London where he was promoted to Professor in 2003. There he became involved in biotechnology and was named London Young Biotechnology Entrepreneur of the Year in 2002. Since moving back to Auckland in 2004 he has continued to focus on research of the signal transduction pathways in the cell and how defects in these lead to the development of cancer and diabetes. He founded biotechnology company Symansis to develop novel tools for drug discovery, and was co-founder of drug development company Pathway Therapeutics.

Notes:

Raymond Stevens, Ph.D.

Title & Affiliation:

Professor, Molecular Biology and Chemistry, The Scripps Research Institute, California, USA
Founding Director, the iHuman Institute, Shanghai, China

E-mail address: stevens@scripps.edu

Telephone: 858-784-9416

Biography:

Raymond Stevens is currently a Professor of Molecular Biology and Chemistry at The Scripps Research Institute in La Jolla, California and the Founding Director of the iHuman Institute in Shanghai, China. Dr. Stevens has pioneered the area of high-throughput structural biology and drug discovery with more than 300 peer reviewed publications. He has been involved in the discovery and development of the marketed drugs Tamiflu™ for influenza virus, Kuvan™ for mild phenylketonuria, Peg-pal™ for classical phenylketonuria, and Alogliptin™ for type 2 diabetes. Dr. Stevens has received numerous awards for his research, including the Sidhu Award (1992), the National Science Foundation's Presidential Young Investigator Award (1994), Beckman Foundation's Young Investigator Award (1994), Lawrence Berkeley Laboratory Outstanding Performance Award (1995), Jouan Robotics Award (2003), USC Alumnus of the Year Award (2005), Chinese Academy of Sciences Distinguished Visiting Professor at Shanghai Institute of Materia Medica (2011) and the Qian Ren Award (2012). Dr. Stevens has helped to establish four U.S. NIH Centers including the most recent GPCR Network. He has founded three La Jolla biotech companies Syrrx (acquired by Takeda), MemRx (acquired by Sagres/Novartis) and Receptos (IPO May, 2013), and most recently a fourth company RuiYi located in Shanghai, China.

Notes:

Takayoshi Suzuki, Ph.D.

Title & Affiliation:

Professor, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Japan

E-mail address: suzukit@koto.kpu-m.ac.jp

Telephone: 81-75-465-7659 Fax: 81-75-465-7659

Biography:

Takayoshi Suzuki received his B.Sc. and M.Sc. from the University of Tokyo (1995 and 1997, respectively), then became a Researcher at Japan Tobacco Inc. (1997–2002). He subsequently joined the Graduate School of Pharmaceutical Sciences, Nagoya City University, as an assistant professor (2003–2009) and lecturer (2009–2011). During that time, he received his Ph.D. from the Graduate School of Pharmaceutical Sciences, the University of Tokyo. He spent one year as a visiting investigator at The Scripps Research Institute, California (with Prof. M. G. Finn; 2007–2008). He has worked as a full professor at the Graduate School of Medical Science, Kyoto Prefectural University of Medicine (2011 to present). His research interests are in the area of medicinal chemistry and bioorganic chemistry, including epigenetic drugs, target-guided synthesis of enzyme inhibitors, and noncovalent interactions between ligands and proteins.

Notes:

Motonari Uesugi, Ph.D.

Title & Affiliation:

Professor and Deputy Director, Institute for Integrated Cell-Material Sciences, Kyoto University, Japan

E-mail address: uesugi@scl.kyoto-u.ac.jp

Telephone: 81-774-38-3225 Fax: 81-774-38-3226

Biography:

Motonari Uesugi is a Professor and Deputy Director of the Institute for Integrated Cell-Material Sciences, Kyoto University, Editorial Board Member of Chemistry and Biology (Cell Press) and MedChemComm (Royal Society of Chemistry), and Editor of Biochemical Journal (London). After completing postdoctoral training in Chemistry Department, Harvard University, Dr. Uesugi started his independent career in Baylor College of Medicine, Houston, where he established an interdisciplinary laboratory in the area of chemical biology. He was tenured in Baylor in 2005, and moved to Kyoto University as a full professor in 2005. He is a recipient of Gold Medal Award, Tokyo TechnoForum 21 (2006), the Pharmaceutical Society of Japan Award for Divisional Scientific Promotions (2011) and German Innovation Award Gottfried Wagener Prize (2011). Dr. Uesugi and his co-workers aim to gain a fundamental understanding of biological events through the study of small molecules.

Notes:

Ming-Wei Wang, M.D., Ph.D.

Title & Affiliation:

Director, the National Center for Drug Screening and the Chinese National Compound Library, China
Professor of Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China

E-mail address: mwwang@simm.ac.cn

Telephone: 86-21-50800598 Fax: 86-21-50800721

Biography:

Following medical training in Shanghai and UCLA, Dr. Wang obtained his Ph.D. from University of Cambridge in 1989. He worked for a couple of US biotech companies a year later and served as a consultant to Merck and UNDP in the mid-1990's. Thereafter, he was engaged in various entrepreneur activities. Dr. Wang was appointed to the faculty of Shanghai Institute of Materia Medica, Chinese Academy of Sciences in 2001 and Director of the National Center for Drug Screening in 2003. In 2004, he was named by Shanghai Pudong Government as a senior business advisor. He becomes the first director of Chinese National Compound Library and one of the key project leaders of China's mega program on drug discovery and development in 2011. He also serves as Honorary Professor at University of Hong Kong, Adjunct Professor at The Scripps Research Institute, Guest Professor at Chinese Academy of Medical Sciences/Peking Union Medical College and Chair Professor at South China University of Technology.

Notes:

Xiaobo Wang, Ph.D.

Title & Affiliation:

Vice President and Chief Technology Officer, ACEA Biosciences, Inc., USA

E-mail address: xbwang@aceabio.com

Telephone: 858-724-0928 Fax: 858-724-0927

Biography:

Dr. Wang received his B.Sc. in telecommunication and information technology from Xidian University, Xi'an, China in 1983 and conducted his Ph.D. and postdoctoral work in biophysical sensor development in University of Wales, UK between 1987 and 1992. Dr. Wang joined University of Texas MD Anderson Cancer Center as a Research Associate in 1993 and became a faculty as an Assistant Professor in 1996. His work mainly focused on the development of biochips and biosensors for biophysical analysis and processing of biological cells in BioMEMS and microfluidic systems. His research work received multiple million dollars funding from US federal and state government agencies such as DARPA, NIH and Texas ATP programs. Dr. Wang joined AVIVA Biosciences as a Senior Director of R&D in 1999, and co-founded ACEA Biosciences in 2002 and is now the Chief Technology Officer and Vice President of ACEA. In his over 10 years industrial endeavor, Dr. Wang developed the breakthrough ion-channel chip technology for high-throughput patch-clamp recording and innovative electronic sensor platform for label-free, real-time cell-based assays. Dr. Wang has published more than 60 research papers and has over 30 issued US patents in various areas of biosensors and biochip applications.

Notes:

David Williams, Ph.D.

Title & Affiliation:

Associate Professor and Director of Graduate Studies, Department of Immunology and Microbiology, Rush University Medical Center, USA

E-mail address: david_l_williams@rush.edu

Telephone: 312-942-1375

Biography:

Following undergraduate studies at Cornell University, Dr. Williams taught chemistry and physics at Aburi Girl's Secondary School in Ghana as a US Peace Corps. It was during this time that his interest in tropical diseases began. He went on to get his Ph.D. in biochemistry at the University of Illinois in 1990. This was followed by postdoctoral research at the Institut Pasteur Lille on a vaccine for schistosomiasis and at Cornell on plant-insect interactions. In 1995 he joined the faculty in Biological Sciences at Illinois State University, where he investigated many aspects of the basic biochemistry and molecular biology of schistosome parasites. He was principle investigator for the physical mapping of the Schistosoma mansoni genome project. In 2008, Dr. Williams moved to his current position at Rush University Medical Center where he continues to study schistosome parasites.

Notes:

Jeanette Wood, Ph.D.

Title & Affiliation:

Consultant, New Zealand

E-mail address: woodjeanette@yahoo.co.nz

Biography:

*Dr. Jeanette Wood is providing cancer drug discovery and development consultancy advice to a number of clients including The University of Auckland and Auckland UniServices. Jeanette's background includes leadership and management of small molecule drug discovery and translational research in several therapeutic areas (cardiovascular, inflammatory diseases and cancer). Her previous experience includes: Vice President at AstraZeneca, Head of Biology at S*BIO Pte Ltd. (Singapore), Translational Pharmacology Unit Head, Member of Oncology Management Team and Angiogenesis Platform Head at Novartis, Hypertension Group Leader as well as Renin Inhibitor Project Leader at Ciba-Geigy.*

Notes:

Beili Wu, Ph.D.

Title & Affiliation:

Professor, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China

E-mail address: beiliwu@simm.ac.cn

Telephone: 86-21-20239065

Biography:

Beili Wu got her Ph.D. degree at Tsinghua University, Beijing in 2006, and worked as a postdoctoral fellow at The Scripps Research Institute in La Jolla, California from 2007 to 2011. She is currently a Professor of Shanghai Institute of Materia Medica (SIMM), CAS. Dr. Wu has been focused on protein structural biology, studying protein structure and function relations for over ten years. She has established a GPCR structural biology research platform at SIMM, and is making great progress on structural studies of many key GPCRs. Her current research is focused on a deep understanding of the molecular details of ligand-recetpor interaction of HIV-1 coreceptors CCR5 and CXCR4, which leads to the development of new therapeutics for AIDS treatment. Dr. Wu and her group solved the crystal structures of CXCR4 and CCR5 in 2010 and 2013, respecitively. These structures provide new clues about the molecular mechanism of HIV-1 viral entry and the interactions between the receptors and their chemokine ligands, as well as the inhibition mechanism of the anti-HIV infection drug maraviroc.

Notes:

Donghai Wu, Ph.D.

Title & Affiliation:

Principal Investigator, Guangzhou Institutes of Biomedicine and Health, Chinese Academy and Sciences, China

E-mail address: dhwu2001@gmail.com

Telephone: 86-20-32015300 Fax: 86-20-32015299

Biography:

Dr. Donghai Wu graduated from Beijing Normal University with a B.S. degree in 1984 and obtained his Ph.D. degree from UT Southwestern Medical Center at Dallas in 1990. He was a faculty member in the College of Pharmacy, University of Florida before joining Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences in 2004 as a Principal Investigator. His major research interests include the molecular mechanism controlling adipocyte development and differentiation, screening and development of novel medicinal compounds for the treatment of metabolic diseases, and development of knockin and knockout animal models to identify and validate potential drug targets important for metabolic disease, etc.

Notes:

Jiarui Wu, Ph.D.

Title & Affiliation:

Vice President, Shanghai Advanced Research Institute, Chinese Academy of Sciences
Professor, ShanghaiTech University, China

E-mail address: wujr@sibs.ac.cn

Telephone: 86-21-54921128

Biography:

Dr. Jiarui Wu received a doctorate degree from Swiss Federal Institute of Technology in Zurich, Switerland, in 1994. He was a postdoctoral fellow in Health Science Center of State University of New York from 1994 to 1997. Since then, he became a professor in Shanghai Institute of Biochemistry, Chinese Academy of Sciences. He has been working on the molecular mechanisms of the intracellular regulation network of cell proliferation, apoptosis and differentiation. He has published more than 80 research papers in international scientific journals. Dr. Wu's academic appointments at present are as follows: Vice President of the Chinese Society of Biochemistry and Molecular Biology, Vice President of Chinese Association of Geriatric Research, Editor-in-Chief of Journal of Molecular Cell Biology, Associate Editors for BMC Systems Biology, Frontiers in Systems Physiology and Chinese Science Bulletin as well as Member of Editorial Board of Cell Research.

Notes:

Kurt Wüthrich, Ph.D.



Title & Affiliation:

Cecil H. and Ida M. Green Professor of Structural Biology, The Scripps Research Institute, USA
Professor of Biophysics, ETH Zürich, Switzerland

E-mail address: wuthrich@scripps.edu

Telephone: 858-784-8012 Fax: 858-784-8014

Biography:

Kurt Wüthrich is the Cecil H. and Ida M. Green Professor of Structural Biology at The Scripps Research Institute, La Jolla, CA, USA, and a Professor of Biophysics at the ETH Zürich, Zürich, Switzerland. His research interests are in structural biology and structural genomics. His specialty is nuclear magnetic resonance (NMR) spectroscopy with biological macromolecules, where he contributed the NMR method of three-dimensional structure determination of proteins and nucleic acids in solution. Kurt Wüthrich's achievements have been recognized by the Prix Louis Jeantet de Médecine, the Kyoto Prize in Advanced Technology, the Nobel Prize in Chemistry, and by a number of other awards and honorary degrees.

Notes:

Tian Xia, Ph.D.

Title & Affiliation:

Professor, Department of Electronics and Informatics Engineering, Huazhong University of Science and Technology, China

E-mail address: tianxia@hust.edu.cn

Fax: 86-27-87544074

Biography:

Dr. Tian Xia obtained his Ph.D. from Iowa State University, majoring Bioinformatics and Computational Biology (BCB). After graduation, he worked as a researh scientist at Biomedical Inforamtics Center, Feinberg Medical School at Northwestern Univeristy and Department of Computer Science and Engineering at University of Minnesota, Twin Cities. Then, he became a faculty member at Department of Electronics and Informatics Engineering, Huazhong University of Science and Technology. He was selected by "1000 Talents: Young Investigator" program in 2013. His research interests are systems biology, machine learning, and network modeling in translational research.

Notes:

Ruiping Xiao, M.D., Ph.D.

Title & Affiliation:

Chair Professor and Director, the Institute of Molecular Medicine, Peking University, China

E-mail address: imm@pku.edu.cn

Telephone: 86-10-62757243 Fax: 86-10-62767143

Biography:

Prof. Ruiping Xiao is the Founding Director of the Institute of Molecular Medicine, Peking University. She was trained as a physician-scientist at Tong-Ji Medical University in Wuhan, China and the Medical School at University of Maryland, where she earned her M.D. in 1984 and Ph.D. in 1995, respectively. She joined the Laboratory of Cardiovascular Science, National Institute of Aging in 1990 as a postdoctoral fellow, and became a tenure-track investigator in 1996 and Senior Investigator in 2003 at National Institutes of Health, USA. Her scientific work has been focused on cardiovascular and metabolic basic as well as translational research. Since April 2010, she has started her directorship in Institute of Molecular Medicine, Peking University, Beijing, China.

Notes:

Xin Xie, Ph.D.

Title & Affiliation:

Deputy Director, the National Center for Drug Screening, China
Professor, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China

E-mail address: xxie@simm.ac.cn

Telephone: 86-21-50801313x156 Fax: 86-21-50800721

Biography:

Xin Xie, Ph.D., Principle Investigator of Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Deputy Director of the National Center for Drug Screening and Adjunct Professor of the School of Life Sciences and Technology, Tongji University. Dr. Xie received her Ph.D. from University of Medicine and Dentistry of New Jersey in 2002, elucidating the neuro-protective roles of gangliosides. Prior to her doctoral work, Dr. Xie obtained her B.S. in Chemistry from Peking University in 1996. Dr. Xie directs drug discovery projects related to G protein-coupled receptors, including target validation, assay development, HTS and preliminary in vivo pharmacology. Her research is mainly focused on autoimmune and neurodegenerative diseases. Dr. Xie's Laboratory is also working on small molecules that can enhance the generation of induced pluripotent stem cells (iPS).

Notes:

Aimin Xu, Ph.D.

Title & Affiliation:

Professor, The University of Hong Kong, Hong Kong SAR, China

E-mail address: amxu@hku.hk

Telephone: 852-28199754 Fax: 852-28162095

Biography:

Dr. Aimin Xu is currently a professor at Department of Medicine and Department of Pharmacology and Pharmacy, also the director of partner State Key Laboratory of Pharmaceutical Biotechnology at the University of Hong Kong. His major research interest is discovery and functional characterization of novel adipokines, hepatokines and other biomarkers involved in the pathogenesis of obesity-related cardio-metabolic complications. His team reported the hepatoprotective and vasculoprotective effects of adiponectin, and also discovered the circulating form of adipocyte fatty acid binding protein (A-FABP) and lipocalin-2 as pro-inflammatory adipokines in both rodents and humans. In addition, his work contributed significantly to the understanding of the molecular basis of adipose tissue inflammation, cross-talk between adipose tissue and blood vessels in the pathogenesis of vascular dysfunctions in obesity and diabetes. His team has developed a series of immunoassays that have now been widely used for clinical diagnostics, high-throughput drug screening, clinical and basic research related to obesity and associated medical complications.

Notes:

Eric Xu, Ph.D.

Title & Affiliation:

Founding Director, Key Laboratory of Receptor Research, Chinese Academy of Sciences

Director and Professor, Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China

Distinguished Principal Investigator, Director of the Laboratory of Structural Sciences, Van Andel Research Institute, USA

E-mail address: eric.xu@simm.ac.cn

Telephone: 86-21-20231976

Biography:

Dr. Xu obtained his bachelor and master degrees in 1985 and 1988, both from Tsinghua University in Beijing, China. He then went to Duke University and the University of Texas Southwestern Medical Center, where he earned his Ph.D. in molecular biology and biochemistry in 1994. Following a postdoctoral fellowship with Carl Pabo at MIT, he moved to GlaxoWellcome in 1996. In July 2002, Dr. Xu joined VARI as a Senior Scientific Investigator and became a Distinguished Investigator/Professor in March 2007. He is currently the Director of the Center for Structural Biology and Drug Discovery of Van Andel Research Institute. In July 2010, Dr. Xu established and served as the distinguished Director of the VARI-SIMM Center for Drug Discovery at Shanghai Institute of Materia, Chinese Academy of Sciences. His recent work on plant hormone abscisic acid receptors, published as a cover article in Nature, has been featured as one of top 10 breakthroughs of 2009 by Science.

Most importantly, his group has recently determined the crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser, the first de novo membrane protein complex solved by this revolutionary technology. The structure reveals an unexpected conformational changes in a GPCR for arrestin coupling, and provides a new paradigm of cell signaling by a highly dynamic molten globule protein – arrestin.

Notes:

Hongxi Xu, Ph.D.

Title & Affiliation:

Dean, School of Pharmacy, Shanghai University of Traditional Chinese Medicine, China

E-mail address: xuhongxi88@gmail.com

Telephone: 86-21-51323089 Fax: 86-21-51323089

Biography:

Professor Hong-Xi Xu is currently a professor and Dean of School of Pharmacy, Shanghai University of Traditional Chinese Medicine. He has published more than 200 SCI papers, and obtained one PCT patent and six US patents.

Prof. Xu obtained his Ph.D. degree in Pharmaceutical Sciences in 1994 from Toyama University, Japan. He has previously served as Scientific Officer in the Institute of Chinese Medicine at the Chinese University of Hong Kong, Deputy General Manager of Hutchison Whampoa (China) Ltd., R&D Director at Shanghai Hutchison Pharmaceuticals. From 2001 to 2010, he served as Deputy Director of Hong Kong Jockey Club Institute of Chinese Medicine. His major social appointments include: Vice President of the Foundation Conference of TCM Pharmaceutical Analysis Specialty Committee of the World Federation of Chinese Medicine, Co-chairman of International Conference of Modernization of Chinese Medicine (ICMCM). He is also an editorial board member of more than 10 scientific journals.

His current research interest is focused on drug discovery from natural resources, as well as development of botanical dietary supplements from herbal medicines.

Notes:

Xiao Xu, Ph.D.

Title & Affiliation:

Director, Hangzhou High-throughput Drug Screening Center, China

E-mail address: xxu@aceabio.com

Telephone: 86-571-28181235 Fax: 86-571-28908607

Biography:

Dr. Xiao Xu is the Director of Hangzhou High-throughput Drug Screening Center. The center was founded in 2008 for small molecule drug discovery and development. He is also the President of ACEA Biosciences, Inc. based in San Diego, California, USA. Before joining ACEA, Dr. Xu was Director of Gene Expression and Amplification at Nanogen, leading a team to develop applications of genetic diagnostics. Prior to Nanogen, Dr. Xu was Staff Research Investigator in Gladstone Institutes, University of California at San Francisco, where he was a principal investigator on Alzheimer's disease, funded by NIH and California State Government. Dr. Xu received postdoctoral training in US Centers for Disease Control and Prevention, and The Scripps Research Institute at La Jolla, California in molecular virology and cancer biology, after he completed his Ph.D. program in Zhejiang University in China. Dr. Xu owns over 15 US patents and filed more than 15 patent applications, and has published over 60 research articles in international journals including Science, PNAS, Nature Biotechnology, as well as Chemistry and Biology.

Notes:

Richard D. Ye, M.D., Ph.D.

Title & Affiliation:

Professor and Dean, School of Pharmacy, Shanghai Jiao Tong Univrersity, China

E-mail address: yedequan@sjtu.edu.cn

Telephone: 86-21-34205430 Fax: 86-21-34204457

Biography:

Prof. Ye received his Ph.D. degree from Washington University in St. Louis (1988). He worked at The Scripps Research Institute as Assistant Professor (1989-1995) and Associate Professor (1995-1998). He joined the University of Illinois at Chicago in 1998, taking tenured professorship at the Department of Pharmacology. In 2010, Prof. Ye was appointed Dean of School of Pharmacy at Shanghai Jiao Tong University (SJTU). He is a Chair Professor at SJTU. The major research activities of Prof. Ye focus on the activation mechanisms for innate immune cells. His group has characterized GPCRs that sense chemoattractants and mediate the activation of innate immune cells. He has authored and co-authored more than 150 SCI research articles and reviews, and chaired an international panel to complete the IUPHAR nomenclature of the formyl peptide receptors. Prof. Ye served as Associated Editor of American Journal of Physiology – Lung Cellular and Molecular Physiology, editorial board of Molecular Pharmacology, and Section Editor for The Journal of Immunology.

Notes:

Deyong Ye, Ph.D.

Title & Affiliation:

Professor of Medicinal Chemistry, School of Pharmacy, Fudan University, China

E-mail address: dyye@shmu.edu.cn

Telephone: 86-21-51980117 Fax: 86-21-51980125

Biography:

Dr. Ye studied medicinal chemistry in Shanghai Medical University and obtained his bachelor and master degrees in 1982 and 1987, respectively. He was employed by Shanghai Medical University (which was merged with Fudan University) as lecturer, Associate Professor and Professor. He received advanced training in University of Perugia, Italy and University of North Carolina, USA. He was previously appointed as Director of Department of Medicinal Chemistry and Vice Dean of School of Pharmacy, Fudan University. His research field is rational design, synthesis and bioassay of small molecular drugs, especially inhibitors of enzymes such as SMS (sphingomyelin synthase), GSK-3β (glycogen synthase-3β), NS5B (non-structural protein 5B) and PGAM1 (phosphoglycerate mutase-1).

Notes:

Yang Ye, Ph.D.

Title & Affiliation:

Deputy Director, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China

E-mail address: yye@mail.shcnc.ac.cn

Telephone: 86-21-50806067 Fax: 86-21-50807088

Biography:

Dr. Yang Ye got his Ph.D. in Shanghai Institute of Materia Medica, Chinese Academy of Sciences in 1992. He was an Alexander von Humboldt fellow and received postdoctoral traning at the Institute of Organic Chemistry, University of Munich, Germany. He is now a full professor and Deputy Director of Shanghai Institute of Materia Medica, Chinese Academy of Sciences. He serves the editorial/advisory boards of 7 international journals and book series, including Phytochemistry Letters, Progress in the Chemistry of Organic Natural Products, Planta Medica, etc. Dr. Ye mainly focuses on the secondary metabolites in traditional herbal plants and their bioactivities. The goal of his research group is to disclose the chemical essence of traditional usages of traditional Chinese medicine and herbal materials, as well as to find potential drug leads by structural modification approaches and collaborative work with pharmacological research groups.

Notes:

Qiang Yu, Ph.D.

Title & Affiliation:

Professor, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China

E-mail address: qyu@shcnc.ac.cn

Telephone: 86-21-50801790 Fax: 86-21-50800306

Biography:

Dr. Qiang Yu received his bachelor degree from Fudan University, Shanghai, China, in 1982 and his Ph.D. in Biology from Brandeis University, USA in 1989. Following that, Dr. Yu had his postdoctoral training at the Whitehead Institute for Biomedical Research of Massachusetts Institute of Technology. He was appointed as an Assistant Professor and subsequently became an Associate Professor at the Department of Medicine and Biochemistry of Boston University Medical School between 1992 and 2002. He returned to China to join the Pharmacology Department of Shanghai Institute of Materia Medica in 2002 and was appointed as a Professor of Pharmacology.

Notes:

Jianmin Yue, Ph.D.

Title & Affiliation:

Professor of Medicinal Chemistry, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, China

Chairman, Department of Natural Products, SIMM

Deputy Director of the Chinese National Compound Library, China

E-mail address: jmyue@mail.shcnc.ac.cn

Telephone: 86-21-50806718 Fax: 86-21-5080678

Biography:

Dr. Yue received his B.S. degree in 1984 from Lanzhou University where he also received his M.S. and Ph.D. in 1987 and 1990, respectively. He was a postdoctoral fellow in Kunming Institute of Botany (KIB), Chinese Academy of Sciences and School of Chemistry, University of Bristol, UK. He was an Associate Professor in KIB from 1994 to 1996. He joined the staff of Unilever Research SIOC as senior scientist and project leader from 1996 to 1999. He was then moved to SIMM where he remains up to now as a professor. He was a visiting professor at Department of Chemistry, The University of Queensland, Australia (2001), and Novartis Pharma AG, Switzerland (2002). He is currently leading his research group focusing on discovery and developing biologically important components from natural resources. Understanding of the chemistry and biological mechanisms of traditional Chinese medicine is also his major research interest. He has published over 230 original research papers.

Notes:

Qiang Zhao, Ph.D.



Title & Affiliation:

Professor, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China

E-mail address: zhaoq@simm.ac.cn

Telephone: 86-21-20239065

Biography:

The research focus of Dr. Zhao is mainly on understanding the relationship between protein structure and function, and the mechanism of recognition mechanisms between protein molecules and substrates. During his Ph.D. study he solved the crystal structure of human Spindlin1, a newly discovered cancer related protein, and then speculated and proved its function from the structure. After expending his work to membrane protein field, Dr. Zhao and co-workers solved the structure of dopamine receptor D3DR, based on which they identified a second pocket for ligand binding. In 2011, Dr. Zhao moved back Shanghai and started his own group, aiming at solving the membrane protein structures involved in human diseases.

Notes:

Xiao-Nong Zhou, Ph.D.

Title & Affiliation:

Director, the National Institute of Parasitic Diseases, the Chinese Center for Disease Control and Prevention, China

E-mail address: xiaonongzhou1962@gmail.com

Biography:

Professor Xiao-Nong Zhou is Director of the National Institute of Parasitic Diseases at the Chinese Center for Disease Control and Prevention, Shanghai, China. He graduated with a Ph.D. in Biology from Copenhagen University, Denmark. His professional work is across the fields of ecology, population biology, epidemiology, and malacology. Professor Zhou is the Chair of the National Expert Advisory Committee on schistosomiasis and other parasitic diseases for China's National Health and Family Planning Commission. He has written extensively on parasitology and parasitic diseases, with more than 100 peer-reviewed publications in international journals, such as N. Engl. J. Med., Lancet, Emerg. Inf. Dis., Inter. J. Parasitol., Adv. Parasitol., PLoS NTDs, Parasites and Vectors, etc. He has collaborated with WHO/TDR, including serving as members for WHO STAC on NTDs, WHO/TDR STAC and WHO Foodborne Burden Epidemiology Reference Group. He has contributed, as former President, to the Regional Network on Asian Schistosomiasis and other important zoonoses since 2000. He is the Editor-in-Chief of Infectious Diseases of Poverty (BioMed Central) and Chinese Journal of Schistosomiasis Control.

Notes:

Weiliang Zhu, Ph.D.

Title & Affiliation:

Professor, Drug Discovery and Design Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China

E-mail address: wlzhu@simm.ac.cn

Telephone: 86-21-50805020 Fax: 86-21-50807088

Biography:

Weiliang Zhu obtained his first degree in 1983 from Yangzhou University, M.Sc. in 1989 from Suzhou University and Ph.D. in 1998 from Shanghai Institute of Materia Medica, Chinese Academy of Sciences. He worked as a lecturer in Yangzhou University from 1983 to 1995 and as visiting lecturer/lecturer in Singapore Polytechnic from 1998 to 2004. Dr. Zhu was then appointed to the faculty of Shanghai Institute of Materia Medica in 2004. His research interests include molecular dynamics simulation on protein function and mechanism, computational chemistry and biology, virtual screening and drug design for various diseases, method and software development for molecular modeling, and drug discovery and design.

Notes:

Yizhun Zhu, M.D., Ph.D.

Title & Affiliation:

Cheung Kong Professor of Pharmacology
Dean, School of Pharmacy, Fudan University, China

E-mail address: zhuyz@fudan.edu.cn, phczhuyz@nus.edu.sg

Telephone: 86-21-51980018 Fax: 86-21-51980008

Biography:

Dr. Yizhun Zhu got his M.D. from Shanghai Jiaotong University in 1989 and Ph.D. at University of Heidelberg in 1995. He joined, as a faculty member of the Department of Pharmacology, National University of Singapore (NUS) in 1998 after postdoctoral training at Kiel University and industrial experience at Hoechst Marion Roussel (now Sanofil). Dr. Zhu is currently a Professor of Pharmacology (also as an adjunct professor of pharmacology, NUS), Dean of School of Pharmacy and Director of Institute of Drug R&D, Fudan University. Dr. Zhu published more than 100 peer-reviewed papers with more than 2600 citations and edited 2 books for his work. Dr. Zhu was awarded Distinguished Young Scientist Grant from National Natural Science Foundation of China in 2008 and Chief Scientist of National Key Research Program (973) and Principle Investigator for the National Platform of Drug Discovery in 2009. Dr. Zhu was awarded Cheung Kong Professorship by the Ministry of Education, China in 2011. His research focuses on molecular pharmacology/drug mechanisms especially for heart and brain. Two novel compounds as drug candidates have completed pre-clinical studies and are moving to clinical trials now.

Notes:

Jian-Ping Zuo, M.D., Ph.D.

Title & Affiliation:

Professor of Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (SIMM), China

E-mail address: jpzuo@simm.ac.cn

Telephone: 86-21-50806701 Fax: 86-21-50806701

Biography:

Prof. Jian-Ping Zuo received his Ph.D. from Osaka University, Japan in 1994 and was a visiting fellow at the National Institutes of Health, USA from 1996 to 2000. He became a professor in the Laboratory of Immunology at SIMM in 2000. Being an expert with rich experience in clinical medicine and laboratory research, Dr. Zuo serves as Director of Immunopharmacology Department in Shanghai Institute of Materia Medica. He is dedicated to discover immunosuppressive and antiviral compounds and explore their therapeutic potential in the treatment of autoimmune diseases and viral infections. Dr. Zuo and his research team have been successful in translational research, leading to some promising drug candidates for the treatment of autoimmune diseases and viral infectious diseases.

Notes:

The National Center for Drug Screening

The National Center for Drug Screening (NCDS) was jointly established in by the Ministry of Science and Technology, the Chinese Academy of Sciences and the Shanghai Municipality Government. At present, it is the only national center specializing in screening for new drugs. As a public technology platform, NCDS offers drug screening services and technical consultations to universities, research institutions and pharmaceutical companies domestically and internationally.

Address: 189, Guo Shou Jing Road
Zhangjiang High-Tech Park, Pudong
Shanghai 201203, China
Tel: 86-21-50801313 800-820-5131
Fax: 86-21-50800721
E-mail: center@mail.shcnc.ac.cn
Website: http://screen.org.cn

国家化合物样品库 CHINESE NATIONAL COMPOUND LIBRARY

The Chinese National Compound Library (CNCL), located at the "Pharma Valley" of China – Shanghai Zhangjiang High-Tech Park, is a major research and development establishment managed by the National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co., Ltd. Together with its six satellite libraries situated in Beijing, Nanjing, Shanghai and Hangzhou, the storage capacity is approaching to 1.8 million compounds of diversified structures. Coupled with this library are the state-of-the-art sample handling, high-throughput/high content screening, information management and quality control systems. As an important material and information resource center, CNCL works with both domestic and international stakeholders to promote sustained drug discovery and development activities worldwide.

Address: 3728, Jin Ke Road
Zhangjiang, High-Tech Park, Pudong
Shanghai 201203, China
Tel: 86-21-51699091
Fax: 86-21-50800712
Website: http://cncl.org.cn